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iii. Abstract 
Complications with protein homeostasis, genetic mutations or post-translational 
modifications can lead to deficits in the correct folding, and therefore function, of proteins. 
These misfolding events are often associated with protein aggregation via amorphous and 
fibrillar pathways. Protein fibrils have long been associated with a range of neurodegenerative 
diseases, such as Alzheimer’s and Parkinson’s diseases, through the formation of fibrillar 
plaques that are deposited in diseased regions of the brain. Current understanding of 
misfolding diseases point to low molecular weight oligomers en route to fibril formation, 
instead of fibrils themselves, as the pathological species. More specifically, the relationship 
between lipid membranes and misfolded oligomers plays a role fibril kinetics and may be a 
vital component of disease aetiology via membrane disruption or leakage by oligomeric pore 
formation.  
To date, there are no effective therapies associated with neurodegenerative misfolding 
diseases, despite great advances in our understandings. To treat diseases such as these we 
require a greater understand of the mechanisms at play. Traditional structure determination 
techniques such as X-Ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy are often not amenable to the study of misfolding proteins given their transient 
nature, therefore new structure determination techniques must be exploited. This thesis 
utilised and developed a combined biophysical approach, with a focus on mass spectrometry 
(MS), to better understand protein misfolding and aggregation. 
Protein quality control systems like chaperones combat misfolding but these can fail, leading 
to disease. The mechanisms of molecular chaperones depend in part on protein morphology 
and can interact differently with the same protein if it undergoes different structural stresses. 
In this work, ion-mobility mass spectrometry (IM-MS) was utilised to understand the 
protective mechanisms of a molecular chaperone, β-casein (β-CN), against the aggregation of 
α-lactalbumin (α-LA). α-LA is capable of both fibrillar and amorphous aggregation, both of 
which were inhibited by β-CN at substoichiometric concentrations. During amorphous 
aggregation, analytical size exclusion revealed α-LA formed stable, high molecular weight 
complex with β-CN. IM-MS coupled with collision-induced dissociation (CIU) described 
transient structural interactions wherein β-CN stabilised α-LA, as well as reduced 
conformational heterogeneity while in the gas-phase. Overall, this data demonstrates the 
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practicality of biophysical techniques, particularly IM-MS with CIU, to explore the interactions 
between misfolding proteins and chaperones. 
α-LA is a powerful model for protein misfolding, but it is not associated with disease. Amyloid 
beta 40 (Aβ40) and α-synuclein (α-syn) proteins are implicated in Alzheimer’s and 
Parkinsons’s diseases, respectively. Here these intrinsically disordered proteins were 
examined to better understand their interaction with the cellular membrane and its effects 
on fibril inhibition by small molecules, EGCG and resveratrol. Large unilamellar vesicles (LUVs) 
were used to model the cellular membrane, and it was revealed that they both increased the 
rate of fibrillar aggregation and decreased the effectiveness of the known fibril inhibitors. 
Using oligomer specific immunoblotting and IM-MS it was shown that EGCG and resveratrol 
work through differing mechanisms, wherein resveratrol targeted the elongation phase of 
aggregation while EGCG targeted the nucleation phase. IM-MS showed EGCG to preference 
binding to more compact forms of monomeric Aβ40 and α-syn, while LUVs influenced 
conformational changes indicative of nucleation. These observations combined to form a 
more detailed mechanistic insight into the protein-lipid-inhibitor relationship and highlighted 
that current approaches toward drug design may be misguided if the effects of lipid 
membranes are not properly considered. 
The transient nature of misfolding proteins can make structural determination complicated 
using traditional high-resolution structure determination techniques like X-ray 
crystallography and NMR spectroscopy. While useful, native- and IM-MS cannot offer specific 
detail in terms of tertiary structure and subunit architecture. Cross-linking MS (XL-MS) has 
emerged as a valuable complementary tool for uncovering structural information from 
proteins. While cross-linkers are available commercially, the rapid emergence of new 
analytical strategies means specific features or combinations of features are not readily 
available, and the highly variable nature of proteins means the optimum cross-linking regent 
may be system specific. To remedy this and enable to a wide range of cross-linker chemistries, 
a modular synthetic protocol was designed to allow for the incorporation custom reactive 
groups, spacer-arms, enrichment motifs and other features. The protocol was used to develop 
a small library containing 8 unique cross-linkers, each containing different features. The 
reagents were optimised using model peptides to monitor efficiency, labile spacer-arm 
fragmentation and derivatisation with enrichment and dye motifs. The wide applicability and 
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straightforward synthesis of the modular protocol aims to remedy the lacking diversity in 
available cross-linkers for broad uptake in XL-MS workflows. 
Overall, the work in this thesis aims to highlight and expand MS-based techniques for protein 
structure determination. The presented examples showcase that investigating transient 
proteins require adaptable techniques like native MS, IM-MS and XL-MS. The combination of 
these and other biophysical techniques provide a toolset capable of handling a great range of 
protein structures deemed too complicated for traditional structure determination 
techniques. 
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Chapter 1: Introduction 
1.1 Protein structure 
Fundamental to life on Earth is the function of proteins which carry out essential biological 
tasks such as catalysis, transport and signal transmission. Proteins consist of amino acids 
transcribed from the genetic information encoded in DNA via messenger RNA. Most proteins, 
following transcription, begin the process of folding to form an intricately defined three-
dimensional structure which allow them to perform a specific biological function. The 
sequence of amino acids in a chain give it specific molecular properties which dictate its 
defined structure, and therefore function, as a biomolecular machine. The importance of the 
protein structure-function relationship was realised in the 1950s when Anfinsen 
demonstrated the refolding of a denatured RNase enzyme, restoring its catalytic activity.1 
The way in which proteins consistently fold into their native states is still not fully understood, 
although a number of models have been proposed to describe formation of protein structure. 
Even small polypeptides would take an astronomical amount of time to fold through the 
random sampling of conformations, according to Levinthal’s paradox,2 given the enormous 
range of potential structures. Despite this, the protein folding process is observed on a 
millisecond timescale.2,3 The process of structure formation is thought to be accelerated by 
sampling a series of increasingly thermodynamically favourable intermediates throughout the 
process of folding, as described by the nucleation-condensation model.4 The native state of a 
functional protein is usually thought to be the state in which its intramolecular contacts are 
at their lowest free energy. We can therefore think of protein folding as the polypeptide chain 
sampling structural conformations upon a three dimensional energy landscape in which the 
folding pathway is guided towards lower energy states (Fig. 1.1).5 As a protein samples lower 
energy conformations it has fewer conformational options as it approaches its native state. 
Hence, although the initial structural freedom is immense, through the nucleation-
condensation model a protein can quickly take on a lower energy state before more intricate 
folding events take place.4  
The nucleation-condensation model proposes that, in the initial folding steps, a protein 
undergoes nucleation wherein large sections of the peptide chain form a native-like nucleus, 
which is followed by the condensation of the remaining unstructured protein. Smaller 
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proteins rely on a rate determining nucleation step that depends on key residues forming 
interactions that allow the remaining structure to form around it. Larger proteins can nucleate 
multiple hydrophobic residue-rich regions which form a hydrophobic core, avoiding solvent 
and allowing the remaining chain to condense and take on the native structure.6,7  
 
Figure 1.1. The free-energy landscape showing collapse of a polypeptide into its lowest energy 
state while conformational freedom is reduced (left). During folding, proteins can sit in 
intermediate states of low energy before reaching the native structure (right). Adapted with 
permission from Dinner, et al. (2000).5 
 
Aside from this process of folding, proteins can undergo further modifications before they are 
utilised in the cell, for example, alternative RNA splicing, the formation of quaternary 
structure through complexation of multiple proteins and through post-translational 
modifcations (PTMs) such as acetylation or phosphorylation.8 These processes help to 
account for the incredible versatility of the proteome attributed to such a comparitively small 
number protein-encoding genes within the human genome (20,000 – 25,000).9 
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1.2 Protein misfolding 
Due to the complex nature of protein folding, the process is susceptible to malfunction, and 
proteins that are ‘misfolded’ will often be inactive or potentially toxic to the cell. Certain 
proteins known as ‘misfolding proteins’ are more prone to this than others. During the folding 
process proteins sample intermediate conformations within the energy landscape, 
sometimes straying from the correct folding process and going into an off-pathway state.10 A 
disruption of cellular homeostasis,11,12 posttranslational modifications (PTMs)13 or genetic 
mutation14 can lower the energy of these normally transient, unfolded intermediates, or in 
the case of proteolytic digestion, form entirely new intrinsically disordered proteins.15  
At high enough concentrations, misfolded proteins can form aggregates. This can be due to 
changes in the cellular environment that cause the partial or full unfolding of proteins 
exposing their normally buried hydrophobic regions, their intrinsic propensity for alternative 
secondary structure formation or changes in the net protein charge, leading to intermolecular 
association.16–19 These conditions can lead to two outcomes; the formation of amorphous 
aggregates or highly-ordered amyloid fibrils. Amorphous aggregates are largely considered 
non-toxic, with nuclear cataracts regarded as the best known disease association, and are 
formed by random hydrophobic associations of insoluble protein.20 Fibrils are formed by the 
stacking of a conserved, repeating β-sheet structure.21 
Amyloid fibrils consist of several ‘protofibrils’ or strand-like protein fibres consisting of 
repeating monomeric protein units stacked together perpendicularly against the fibril axis, 
held together through strong β-sheet interactions (Fig. 1.2). This process is typically labelled 
as nucleation-dependent, where misfolded proteins associate to form small oligomers 
beginning the ‘lag phase’. The lag phase ends with the creation of a nucleus, following a shift 
toward an increase in β-sheet content,22 which is capable of rapidly recruiting monomeric 
units to incorporate into the protofibril. The protofibril extends during an ‘elongation phase’ 
and multiple protofibrils combine to form a mature amyloid fibril, reaching equilibrium with 




Figure 1.2. Pathway of amyloid aggregation. The stacking of amyloid proteins, held together 
by beta-sheet interactions perpendicular to the fibril axis (indicated by the arrow) (left). 
Adapted with permission from Wasmer, et al. (2008).23 During the nucleation phase, 
misfolded proteins form low-molecular weight oligomers until a seed capable of fibrillation 
forms, beginning the elongation phase. Protofibrils then accumulate to form mature fibrils 
(right). Adapted with permission from Kulikova, et al. (2015)24 
 
Amyloid fibril plaques are the pathological indicator for a wide variety of debilitating diseases 
known as misfolding diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases.25 
While the exact mode of disease aetiology is not fully understood, the presence of amyloid 
fibril build up in the diseased cells of sufferers led to the formulation of the amyloid 
hypothesis,26 implicating fibrils as the cause of disease. However, current research has shown 
that while plaques may be an indicator of misfolding disease, they may not actually be 
toxic,27,28 whereas the causative agents instead are likely the low-molecular weight oligomeric 
species en route to fibril formation.29–32 
The mechanism by which the low-molecular weight oligomers exert their toxic effects is still 
not well defined, although it has been suggested that the process may involve the interaction 
between cellular membranes and amino acid residues of the protein that are normally buried 
within the globular structure. Interactions between fibrillogenic proteins and lipid 
membranes, as well as other surfaces, have been shown to accelerate fibril formation rates 
and affect mature fibril morphology indicating some form of interaction is taking place33–37 
but the process, and whether it is varied or a unified mechanism is not well understood.38–41 
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Current opinion also suggests that oligomers may insert themselves within the bilayer or bind 
to its surface, leading to membrane thinning and membrane leakage, or form annular 
aggregates that allow for unchecked ion movement, potentially leading to apoptosis (Fig. 
1.3).36 This impairment of membrane function may potentially underlie the toxicity observed.  
Due to the toxic effects of amyloid formation, cells have developed a variety of preventative 
measures to correct or destroy misfolded proteins. One component of the protein 
homeostasis network is formed by ‘chaperones’, proteins designed to increase the efficiency 
of successful protein folds or correct misfolded proteins. Chaperones belong to two broad 
mechanistic families, holding and folding chaperones.42 Holding chaperones are energy 
independent and prevent further unfolding or aggregation of proteins, whereas folding 
chaperones are ATP-dependent and can ‘refold’ proteins to restore function. Unfortunately, 
the effectiveness of chaperones is not boundless, and notably many diseases due to protein 
misfolding begin with mutations to genes responsible for protein chaperones.43–45 From an 
exogenous perspective, natural polyphenols have long been scrutinized for their ability to 
prevent the fibrillation of misfolding proteins.46 For example, epigallocatechin-3-gallate 
(EGCG), the primary polyphenol in green tea, has shown to stall the progression of amyloid 
formation, as well as restructure fibrillated proteins.47–49 While no effective therapeutic 
compounds currently exist to treat amyloid diseases at the target misfolding protein level, 
further attention on small molecule inhibitors such as natural polyphenols is required to 
exploit their effects more fully. 
 
Figure 1.3. Endoproteolytic cleavage of amyloid precursor protein (APP) forms the misfolding 
protein, amyloid β (Aβ). Misfolding protein oligomers interact with the lipid bilayer, 
destabilising it and leading to apoptosis. Oligomers may interact on the surface, insert into 
the membrane or form annular pores, allowing for the unchecked mixing of the outer- and 
inner-cellular environment. Adapted with permission from Niu, et al. (2018)50 
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1.3 Protein structure determination 
 Methods for protein structure determination 
To properly understand disease due to protein misfolding we must first understand the 
structure and molecular interactions of the proteins involved. One traditional method for 
protein structure determination is X-ray crystallography, a technique that is capable of 
atomic-level resolution but shows proteins as rigid structures locked within a crystal lattice.51 
This goes against the understanding that proteins sample a range of energetically favourable 
states governed by the thermodynamic landscape of the environment. On top of this, only 
between 2 – 10 % of proteins are amenable to crystallisation.52 Nuclear magnetic resonance 
(NMR) spectroscopy is capable of revealing protein structure while in solution, taking into 
account their dynamic nature, but has a multitude of limitations such as the requirement for 
relatively large amounts of sample and typical application to proteins below 40 kDa (although 
NMR has been sporadically applied to significantly larger structures53,54). Cryo-electron 
microscopy (cryo-EM) has emerged as a powerful tool for protein structure determination in 
recent years, capable of 1 Å level resolution,55 but is also not without limitations. Up until 
recently, cryo-EM was primarily used for the analysis of proteins at sizes exceeding 150 kDa, 
and although a small percentage (<1%) of structures below this have been determined, there 
are complications with image resolution that depend heavily on the heterogeneity of the 
protein of interest.56,57 
These techniques have many strengths, in particular their resolution, but can require specific 
circumstances to be fully applicable. Misfolding proteins present intrinsic difficulties for 
structural determination due to their labile and transient nature, and as such, advances in the 
development of therapeutics and understanding disease aetiology have been limited. 
 Mass spectrometry 
Mass spectrometry (MS) has emerged in recent decades as a powerful technique for 
uncovering structural features of proteins and is used as a complement or even alternative to 
more traditional structure determination techniques. While initially developed in the 1900s, 
technologies allowing the analysis of protein structure have only been available within the 
late 20th century.58 MS has since proved itself an integral part of the protein structure 
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determination toolset due to its flexibility in handling both denatured and native protein 
samples, and ability to reveal peptide sequences, subunit stoichiometries, low-resolution 3D 
structure and more. The ability to handle a wide range of samples complimented by the 
hybrid approach of combining MS with other techniques, allows it to offer information on a 
wide range of proteins at different levels of structure. 
The basis of MS relies on ionisation of a sample then separation of the analytes by their mass 
to charge ratio (m/z). Until the development of electrospray ionisation (ESI) and matrix-
assisted laser desorption/ionization (MALDI), introduction of analytes to the gas phase would 
typically destroy macromolecules like proteins.58 ESI as a ‘soft ionisation’ technique opened 
the door to the possibility of MS for small, non-volatile biomolecules all the way up to entire 
viral assemblies.59  
ESI produces gas-phase ions by transferring them from the solution into the gas-phase in a 
‘gentle’ manner that not only reduces the likelihood of molecular fragmentation but can also 
maintain non-covalent interactions.60–63 The sample solution is ejected through a small 
opening, typically a capillary needle, between an electric potential. Due to the small size of 
solvent ejection tip the local electric field is very high, leading to the formation of a ‘Taylor 
cone’ as the sample aerosolises, producing droplets that rapidly desolvate (Fig. 1.4).64 This 
process is often assisted by heat to aid in evaporation of clustered solvent molecules. 
Ionisation is possible in both positive and negative modes depending on the polarity of the 
electrical potential that is applied. In positive mode, protons, sodium, ammonium and other 
cations in the solvent can give droplets charge, as well as fixed charge motifs on the analyte. 
In negative mode this is achieved by the presence of hydroxide, acetate or deprotonation of 
acids in the sample.65 As droplets travel toward the MS inlet they evaporate, increasing the 
relative charge density of the droplets until Coulombic repulsions trigger a ‘droplet fission’ 
which ejects a smaller, more highly charged droplet.66 This process repeats until a solvent 
free, gas-phase ion is produced which can be separated and analysed,66 although the 
hydrophilicity of many biomolecules can give rise to incomplete desolvation and result in less 
well resolved mass spectra.67,68 Building upon this process has led to the development of 
nanoESI which utilises a small needle typically coated in conductive material to assist transfer 
of charge. This requires only nanolitre quantities of sample solution, typically at low 
micromolar protein concentrations, for analysis.62 Aside from lower sample requirements, 
13 
nanoESI has also been shown to improve spectral resolution as smaller initial droplets 
effectively reduces the relative concentration of salts and potential contaminants in the 
droplet and aids desolvation.69 
 
Figure 1.4. The nanoESI-MS process for ionisation of a protein. Solvent forms droplets which 
undergo desolvation followed by ‘droplet fission’ leading to solvent free gas-phase ions. 
Adapted from Konermann, et al. (2013).66 
 
Following ionisation, analytes are separated by their mass to charge ratio (m/z). ESI is 
commonly paired with a time-of-flight (TOF) mass analyser for protein anlaysis. TOF 
separation works on the basis that low mass, highly charged species travelling over a fixed 
distance under the influence of an electric potential will reach the detector faster than high 
mass, lower charged species. Packets of ions are transmitted to the TOF analyser where they 
are pulsed for detection, and ion masses are resolved based on the time taken to pass the 
known distance of the analyser using a calibration approach (Fig. 1.5).  
 
The quadrupole, another mass analyser, is often paired with ESI and TOF analysis as a hybrid 
MS instrument (Q-TOF). The quadrupole consists of four parallel rods to which RF and DC 
voltages are applied to produce oscillating electric fields. Ions are transmitted based on how 
they interact with the electric field generated, with ions of a particular m/z having a stable 
trajectory through the quadrupole.60 This is advantageous because ions of a specific mass can 
be selected and subjected to a collision-induced dissociated (CID) cell before TOF separation. 
CID activates ions by propelling them into an inert gas, such as helium, nitrogen or argon. This 
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leads to an increase in the energy of the analyte causing it to fragment in a predictable 
manner. Calculating the expected mass losses due to amino acids detaching from the peptide 
allows for the structure of the protein can be determined.70 The practicality of this technique 
paired with a QTOF MS lies in the ability to isolate individual masses, fragment them and then 
analyse the fragmentation products as this can give information such as subunit 
stoichiometries of proteins, small molecule identification and much more.60,70–74  
Possibly the most important development in biological MS has been the advent of bottom-up 
proteomics, lending itself to the utilisation of CID as a protein sequencing technique. In this 
typical workflow, proteins are proteolytically digested and resulting peptides are separated 
by liquid chromatography (LC). Individual peptide ions are then selected based on m/z then 
fragmented by CID and the resulting products analysed. The sequential fragmentation pattern 
of activated peptides between the amide bond, known as b/y-ions, or the nitrogen and alpha-
carbon, known as c/z ions, or between the carbonyl and the alpha-carbon, known as x/y ions, 
the peptide sequence can be reverse-engineered from the fragmentation spectra which is 
then cross-checked with an online database (Fig. 1.5).75 The method of activation used will 
preference a particular output of fragmentation pattern, for example CID preferences b/y ion 
formation whereas another dissociation methods, electron transfer dissociation (ETD), 
preferences c/z ions.76 Modern proteomics analysis of this nature typically utilises an orbitrap 
mass analyser due to superior mass resolution and accuracy when compared with other 
instruments.77 Orbitraps, unlike TOF, do not measure mass by ion travel time along a known 
path; instead the ions oscillate around a central electrode, generating an image current which 




Figure 1.5. Bottom-up proteomics. (A) Peptides selected by MS/MS and subject to CID 
fragmentation yield b/y ions while analogous activation techniques can lead to c/z and a/x 
ions. (B) The fragmentation spectra are analysed by software, or by hand, calculating the mass 
losses due to amino acid dissociations giving a peptide sequence. These mass losses are 
crosschecked against online databases to identify protein with which they belong. Adapted 
from Zhang, et al. (2013).79 
 
 Native mass spectrometry 
With the advent of ESI it became possible to not only ionise large biomolecules without 
fragmentation, but also maintain non-covalent interactions that determine protein higher 
order structure. Early work with ‘native MS’ revealed subunit stoichiometries of horse liver 
and yeast alcohol dehydrogenases as a dimer and tetramer, respectively, an experiment 
considered impossible years earlier.80 Current applications of native MS reveal information 
on vastly more complicated protein complexes. For example Gordiyenko, et al.81 revealed the 
GTP-bound translation initiation factor 2 to be a decamer rather than the previously thought 
pentamer, changing paradigms in structural biology. It is not only possible to observe protein-
protein interactions by native MS, but a variety of studies apply CID and MS to understand 
protein-ligand binding, using CID activation to determine the dissociation constants of protein 
assemblies.82 For example, Yen, et al.83 investigated binding affinities between the human 
purinergic receptor P2Y1 and adenosine 5′-diphosphate, -triphosphate and the drug 
MRS2500, highlighting the effectiveness of native MS as a tool for investigating non-covalent 
protein interactions. Reading, et al. used native MS and titration with detergents and lipids, 
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as well as temperature modulation, to establish equilibria between tetrameric and 
pentameric oligomers of the mechanosensitive channel of large conductance or MscL, 
demonstrating the ability to apply native MS to membrane proteins which are particularly 
challenging to structural biology. 
While native MS is a powerful technique for investigating complex architectures, it can also 
be used to probe the relative foldedness of a protein through changes in the charge state 
distribution of the protein ion.84 This is due to the fact that unfolded proteins expose more 
ionisable residues to the solvent, shifting the charge state distribution to more highly charged 
ions.66 This observation has been exploited to gain insight into the stability of proteins,85 for 
example, through monitoring the denaturation of ferricytochrome c by acid in differing 
methanol concentrations,86 and in recent years has been further enhanced by coupling of ion 
mobility technologies with MS. 
 
 Ion-mobility mass spectrometry 
This gentle conditions of native MS is particularly beneficial for the analysis proteins that are 
unable to be crystalised and are difficult to produce recombinantly, resulting in low protein 
yields like membrane proteins,87 and misfolding protein aggregates.88 Furthermore, native 
MS with ion-mobility (IM-MS) is capable of measuring higher-order structural features of 
proteins regardless of their dynamic nature, which is an intrinsic property of amyloid-forming 
proteins. 
During IM-MS, ions are separated based on their three-dimensional, rotationally-averaged 
structure known as the collisional cross-section (CCS), as well as their m/z. In a traditional drift 
tube IM experiment, ions tumble through the IM cell under the influence of an applied voltage 
which moves them through a tube of inert gas passing in the opposite direction. Larger ions 
encounter more collisions with the gas, slowing their passage, whereas ions with a smaller 
CCS encounter fewer collisions and travel faster.89 This yields an arrival time distribution (ATD) 
for ions which can be used to calculate their CCS, using the Mason-Schamp equation90: 












Where Ω is the CCS, 𝐾0 is the reduced mobility (depending on temperature and pressure of 
the drift tube), 𝑧 is the charge of the ion, 𝑒 is the elementary charge, 𝑁 is the number density 
of the drift gas, 𝜇 is the reduced mass of the ion-neutral drift pair has pair,  𝑘𝐵 is the Boltzmann 
constant and 𝑇 is the gas temperature.91  
Since the concept of the original drift tube was described a century ago, many developments 
in IM-MS have been made. For example, travelling wave ion-mobility spectrometry (TWIMS), 
the mode of separation used in this thesis, was incorporated into the first commercial IM-MS 
instruments and offered enhanced detection of large analytes such as proteins. A TWIMS 
sector is comprised of a series of stacked ring ion guides capable of generating 
radiofrequencies. The radiofrequency voltages are set at alternating polarities which confine 
ions radially, while a current passing through the centre pushes ions axially. The axial voltage 
is pulsed, creating a ‘travelling wave’ that pushes the ions through the IM sector. Ions of a 
lower mobility experience a greater number of ‘roll over’ events, taking longer to reach the 
detector.91 Larger ions experience more roll over events, interacting with the gas filled cell, 
giving separation and a means to measure CCS by a calibration approach from drift times (Fig. 





Figure 1.6. Schematic diagram of a Waters Synapt G1 IM-MS. The analyte is ionised by ESI and 
separated by its mass to charge ratio in the time-of-flight mass analyser. The individual mass 
can be selected by the quadrupole and be activated in either the trap or transfer CID cells. A 
TWIMS drift cell separates ions based on their mobility. Adapted with permission from 
Pringle, et al (2007).93  
 
While originally applied to small molecules, the first studies using native IM-MS in a protein 
context confirmed the 11-member ring topology of trp RNA in the gas-phase in conformations 
consistent with high resolution structures, while binding of tryptophan and RNA were shown 
to stabilise the complex.94 The ability to retain solution phase structural properties as 
demonstrated by IM highlighted the potential of the technique for protein structure 
determination. IM-MS is particularly well suited to proteins that are difficult to gain structural 
information on, like membrane and misfolding protein. This was showcased when Smith, et 
al. observed that β2-microglobulin formed elongated oligomeric structure before 
aggregation,95 and more recently when Österlund, et al. demonstrated that IM-MS can be 
used to gain structural insights into highly transient amyloid β 42 (Aβ42) oligomers. Native 
IM-MS revealed Aβ42 formed hexameric micelle clusters which, when compared with 
computational models, showed pore like structures, shedding light on potential disease 
mechanisms.96 
Further exploration of IM-MS as a protein structure determination technique has led to the 
development of collisional-induced unfolding (CIU). In this approach, the ATDs of native-like 
proteins in the gas-phase are monitored while CID voltages are increased. This allows for 
observation of protein unfolding as the ATD increases with increased collision energy. For 
example, utilisation of this technique has revealed that the allosteric binding of HIV protease 
inhibitors conferred stabilisation of human zinc metalloprotease (ZMPSTE24) by noting 
increased collision energies were required to unfold apo-ZMPSTE24.97 
 
 Cross-linking mass spectrometry 
MS in conjunction with chemical crosslinking (XL-MS) is another emerging technique for 
understanding tertiary and quaternary protein structure. XL-MS works by chemically ligating 
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specific amino acids within a protein of interest, giving interspatial distance constraints that 
allow for the interrogation of protein binding interfaces, intramolecular contacts and 
stoichiometry.98 A typical chemical crosslinker consists of two main components; the spacer 
arm and the reactive group (Fig. 1.7). The reactive group consists of a chemical moiety that 
irreversibly reacts with amino acids. Common reactive groups include n-hydroxy succinimide 
(NHS) for basic residues, hydrazide groups for acidic residues and maleimides for thiol 
containing residues.  
 
Figure 1.7. A simple chemical crosslinker, disuccinimidyl glutarate (DSG), with a carbon chain 
spacer arm and two n-hydroxy succinimide reactive groups which target basic protein sites 
like lysine. 
 
Cross-linked peptides are typically sequenced by bottom-up proteomics (Fig 1.8).98–101 Cross-
linking has the potential to yield three kinds of modifications: interpeptide links, intrapeptide 
links and ‘dead-end’ links whereby a crosslinker has attached to the protein at one end but 
hydrolysed on the other. XL-MS software calculates the added masses from the three possible 
cross-link modifications and scans the MS/MS spectra and to identify matching sequence 
data, and therefore linkage sites.100 The most commonly utilised examples of XL-MS software 
currently are pLink,102 MeroX103 and XlinkX.104 Once identified, these linkages can give 
information on the interspatial arrangements of amino acid residues through the spacer-arm 
which, since it is a known length, acts as a ‘molecular ruler’.101 This data can be used to guide 
3D computational structure modelling, build linkage maps and establish subunit topology. 
When combined with complimentary techniques like cryo-EM, XL-MS can reveal subunit 
stoichiometries, binding interfaces and 3D structures, perhaps best exemplified by Plaschka, 
et al. who determined the structure of co-activator complex Mediator (cMed) of 
Saccharomyces cerevisiae.105 Low resolution EM data, likely due to heterogeneity of the cMed 
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structure, was aided by XL-MS to model the RNA polymerase II–Mediator complex and show 
how it was stabilised by several transcription factors. 
 
Figure 1.8. Once selected, a cross-linker is reacted with the protein of interest. The protein is 
digested, often from an excised gel electrophoresis band, then digested. The protein is then 
analysed by liquid chromatography MS and the cross-links are identified by spectral matching 
with database searches. Adapted with permission from O’Reilly, et al. (2018).100 
 
XL-MS allows for protein structural information to be covalently ‘locked’ in place during 
analysis, yielding a ‘snapshot’ of a protein configuration. This presents advantages for 
capturing highly dynamic proteins in various states that are only accessible in solution. For 
example, this was demonstrated when Schmidt, et al. showed cross-linking could lock in place 
conformational changes of chloroplast ATPase.106 Using XL-MS, different conformational 
states were covalently trapped, with and without phosphorylation of the ATPase, suggesting 
the post-translational modification was essential to the closed and opened form of the 
complex. The ability to study dynamic protein structures is not only relevant to folded native 
proteins but also of particular interest to elucidating structural information from misfolding 
proteins and oligomers. For example, McDonald, et al. utilised XL-MS to better understand 
the prion protein (PrPc) which, due to regions of intrinsic disorder, is difficult to categorise 
with traditional protein structure determination techniques.107 In this study they were able 
to define intramolecular contacts between the C- and N-terminal domain that are considered 
important to disease pathology.  
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The techniques listed describe the ability for MS interrogation of native structures and subunit 
architectures from proteins that are unamenable to traditional structure determination 
techniques. Protein structure determination is essential to understanding misfolding diseases 




This thesis aims to demonstrate the use of an MS-based approach to explore proteins that 
are less amenable to traditional structure determination techniques. i) The effects of 
chaperones on binding and stability of misfolding proteins will be explored. ii) The ability of 
lipids to impact protein aggregation and the efficacy of fibril inhibitors. iii) A modular synthetic 
protocol will be developed for synthesis of a cross-linker library to add diversity to a currently 
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Under certain cellular conditions functional proteins undergo misfolding, leading to a 
transition into oligomers which precede formation of amyloid fibrils. Misfolding proteins are 
associated with a variety of neurodegenerative diseases such as Alzheimer’s disease and 
Parkinson’s disease. While the importance of lipid membranes in misfolding and disease 
aetiology is broadly accepted, the influence of lipid membranes during therapeutic design has 
been largely overlooked. This study utilized an integrated biophysical approach to provide 
structural and mechanistic insights into the effects of two lipid membrane systems (anionic 
and zwitterionic) on the inhibition of Aβ40 and α-synuclein amyloid formation at the 
monomer, oligomer and fibril level. Large unilamellar vesicles (LUVs) were shown to 
substantially decrease the effectiveness of two well-known fibril inhibitors, (-)-
epigallocatechin gallate (EGCG) and resveratrol, however, use of immunoblotting and native 
ion-mobility mass spectrometry revealed this occurs through varying mechanisms. Oligomeric 
populations in particular are differentially affected by LUVs in the presence of resveratrol, an 
elongation phase inhibitor, compared to EGCG, a nucleation targeted inhibitor. Native Ion-
mobility mass spectrometry showed EGCG interacts with compact forms of monomeric Aβ40 
and α-synuclein, while LUVs induce conformational transitions indicative of nucleation before 
elongation. The competing effects of the lipids and inhibitor, along with reduced inhibitor 
binding in the presence of LUVs, provides a mechanistic understanding for the decreased 
inhibitor efficacy in a lipid environment. Together, this study highlights that amyloid inhibitor 
design may be misguided if the effects of lipid membrane composition and architecture are 
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Many intrinsically disordered proteins (IDPs) are prone to aggregation in the form of amyloid 
fibrils, and the accumulation of neuronal plaques containing these aggregates are hallmarks 
of a variety of neurodegenerative diseases. For example, extracellular plaques composed of 
amyloid β (Aβ) and intracellular Lewy bodies containing α-synuclein (αS) are associated with 
Alzheimer’s disease and Parkinson’s disease, respectively. However, despite strong 
correlative links, the molecular mechanisms by which these IDPs contribute to the disease 
aetiology is still poorly understood.  
In periods of cellular stress, amyloidogenic proteins can enter an aggregation pathway 
commencing with a nucleation-phase in which misfolding proteins restructure to form 
aggregation-prone, prefibrillar species. This is followed by an elongation-phase in which 
monomeric proteins are recruited from solution to form mature fibrils [1,2]. Current research 
suggests the low molecular weight, soluble, oligomeric species formed early on the 
aggregation pathway are primarily responsible for neurotoxic effects rather than the mature 
amyloid fibrils [3–7]. Small, pre-fibrillar species have been shown to be more toxic than the 
plaques that they eventually form [6–8], and smaller oligomeric species have been shown to 
exert enhanced toxicity [9]. While focus has shifted in this regard from fibrils to monomers 
and oligomers, further research is required to understand the structure of toxic oligomeric 
species to better guide therapeutic development. 
Importantly, many recent studies have highlighted the critical role that membrane 
composition and curvature plays in amyloid disease propagation through the interactions 
between misfolded oligomeric species and  plasma/organelle membranes. Whether this is 
due to a unifying mechanism or a variety of molecular processes driving pathogenesis is yet 
to be fully understood [10–13]. For example, Aβ has been shown to interact with neuronal 
cell membranes whereby oligomeric forms of the protein cause membrane leakage and 
transmission of ions, disrupting ionic homeostasis particularly for Ca2+, and resulting in 
neuronal cell death [11,14–16]. On top of this, studies show that lipid bilayers (and other lipid 
forms) may increase the aggregation propensity of misfolded proteins as well as alter 
monomeric and oligomeric structures [17–19]. Also of importance is membrane composition, 
as differing lipid mixtures induce a variety of different effects including increased rate of αS 
nucleation in the presence of anionic lipid membranes [20], while shorter chain phospholipids 
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have been shown to halt Aβ fibril formation at low concentrations and accelerate it at higher 
concentrations [21]. Anionic lipids have been shown to interact with many misfolding proteins 
such as, Aβ, αS and human islet amyloid polypeptide and increase rates of fibrillar elongation 
[22,23]. Other components of the cellular membrane such as cholesterol and gangliosides can 
also influence fibril kinetics and morphology [13,24–26]. The lipidome of neurons is 
complicated, diverse and is altered with age and disease states. After 20 years of age the total 
lipid content of the brain decreases, as does the concentration of sphingomyelins and 
cholesterol, although different neurons are affected more than others, further reinforcing the 
importance of understanding of amyloid formation in diverse lipid environments [27]. 
The economic and social burden caused by amyloid diseases makes the hunt for an effective 
therapeutic incredibly important [28]. Natural polyphenols are of great interest due to their 
antioxidant effects and have been shown extensively to directly inhibit the aggregation of a 
wide range of misfolding proteins, particularly Aβ and αS [29,30]. Two compounds that have 
been widely studied and demonstrated efficacious anti-amyloid activity, (-)-epigallocatechin 
gallate (EGCG) and resveratrol, are natural products isolated from green tea and red wine, 
respectively. EGCG has been shown to not only inhibit fibril formation but also remodel Aβ 
into smaller, nontoxic, amorphous aggregates [30–33]. Resveratrol, whilst a promising 
candidate in animal studies [34,35], has been shown to stop Aβ fibril formation through a 
capping mechanism, preventing large scale fibrilization while having no effect on oligomer 
formation [36–38]. Despite the promise of these studies, they and many others largely ignore 
the influence that a lipid environment plays on amyloid formation as well as the effectiveness 
of inhibitors in this highly dynamic environment [39]. To better develop effective small 
molecule inhibitors of misfolding and aggregating proteins we must understand their 
interactions in the physiological environments in which these inhibitors will be acting. 
IDPs are, by definition, highly dynamic and heterogeneous, making them not amenable to 
study by traditional structural biology techniques such as x-ray crystallography due to the 
transient nature of the protein structure itself. Other methods like nuclear magnetic 
resonance (NMR) spectroscopy, circular dichroism (CD) spectroscopy and fluorescence 
spectroscopy present data on a global average rather than the collection of unique structural 
states and oligomers that constitute a transient mixture. The combination of nano-
electrospray ionisation (nESI) with native ion-mobility mass spectrometry (IM-MS) allows for 
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gentle ionisation of proteins into the gas-phase, preserving important tertiary and quaternary 
structures, while separating based on mass to charge (m/z) as well as a rotationally averaged 
size (or collisional cross section, CCS) [40–42]. It therefore offers a useful alternative analytical 
method to probe the heterogeneous and dynamic states of IDPs during protein aggregation, 
and investigate the impact of small molecules on this process. 
Here we have utilised IM-MS in an integrated biophysical approach to better understand the 
role of lipid membranes in protein misfolding diseases at distinct stages along the aggregation 
pathway, from monomeric structure to fibril morphology. We explore differences in the 
aggregation dynamics of Aβ40 and αS in the presence of two membrane models, namely 
unilamellar vesicles (LUVs) composed of zwitterionic 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (PC) or a mixture of anionic 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-
rac-glycerol) (PG) with PC (herein PCPG). These model systems were chosen as PC is a major 
phospholipid in human neuronal membranes and PG acts to create a negative bilayer surface 
charge, which are major components within grey and white matter [27]. The relative efficacy 
of two small molecule inhibitors, EGCG and resveratrol, was evaluated in these lipid 
environments and the effects of these variables on protein structure and aggregation 
propensity were interrogated. This study highlights the interplay between misfolding 
proteins, phospholipid membranes and fibril inhibitors, and may inform the design of more 
effective therapies to take into account the influence that lipid environments impose on 
disease development and inhibition. 
 
3.3 Experimental Procedures 
Human Aβ40 (lyophilised powder) was purchased from Anaspec (Fremont, USA). 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-
rac-glycerol), were purchased from Avanti Polar Lipids (Alabaster, USA). EGCG, resveratrol 




 Preparation of Aβ40, αS and LUVs 
Expression and purification of human αS (UniProt accession number: P37840) was performed  
as described previously [43].  Pre-formed αS seed fibrils were produced from the monomeric 
protein preparation as described previously [44]. Aβ40 was pre-treated with NH4OH to ensure 
monomerisation according to the method described by Ryan, et al [45]. Aliquots were snap 
frozen and stored at -80 °C and were only defrosted immediately before use. LUVs were 
extruded using an Avanti Mini-Extruder with 0.1 µm extruder filters (Millipore, Billerica, USA) 
according to the manufacturer’s instructions. LUV diameters were confirmed by dynamic light 
scattering (DLS) and transmission electron microscopy (TEM). 
 
 Dynamic light scattering 
LUV diameters were measured by dynamic light scattering using a Malvern Zetasizer nano ZS 
(Malvern Instruments, Malvern, UK). LUVs were characterised at a concentration of 1.5 mM 
with a 633 nm laser at a back scattering angle of 173°. 
 
 Thioflavin T assays 
Fibrillar aggregation was monitored in real-time using a ThT fluorescence assay [46]. Primary 
nucleation-mediated fibrilization of Aβ40 (50 µM) and αS (150 µM) was performed in 100 mM 
ammonium acetate (pH 7.4) and thioflavin T (ThT) (40 µM) in the absence and presence of 
LUVs (1:30 molar ratio; protein:lipid) [24]. Inhibitor concentrations were based on previously 
established concentrations [33,47]. Fibrilization of αS (50 µM) in the presence of short seed 
fibrils (2.5 % w/w) was performed to examine the effects on fibril elongation in the absence 
and presence of LUVs and inhibitors. Samples were plated (50 µL/well) into sealed 384-well 
microplates (Greiner Bio-One, Kremsmünster, Austria) and fibril formation was monitored 
using a FLUOstar Optima microplate reader (BMG Lab Technologies, Melbourne, Australia) 
over a period of 20 h (Aβ40), 25 h (seeded αS) and 120 h (unseeded αS) at 37 °C with shaking 
(double orbital, 50 rpm) for 30 s prior to fluorescence measurement. ThT fluorescence was 
measured with an excitation and emission wavelength of 440 and 490 nm, respectively. All 
data, except for seeded αS assays, were fitted with non-linear sigmoidal dose response to 
calculate and compare the rate of fibril elongation as well as the extent of fibril formation (i.e. 
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inhibition). Seeded αS assays were fitted with a one-phase exponential association. All ThT 
kinetic data were analysed using Prism 8.0 (GraphPad Software, La Jolla, USA) and all assays 
were performed at least three times and are reported as mean ± SEM. 
 
 Transmission electron microscopy 
Samples were taken immediately at the conclusion of the ThT assay and placed directly (3 µL) 
onto a carbon-coated 400-mesh nickel TEM grid (ProSciTech, Thuringowa Central, Australia) 
[32]. Grids were washed with 0.22 μm filtered MilliQ water and stained with 2% (w/v) uranyl 
acetate solution. Samples were viewed using either a CM100 transmission electron 
microscope (Philips, Eindhoven, Netherlands) or a Tecnai G2 Spirit TEM (FEI, Oregon, USA) 
with a magnification of 45 000×. 
 
 Immunoblotting 
The relative abundance of various morphological states (i.e. monomer, oligomer or fibril) of 
Aβ40 and αS was assessed by immuno-dot blotting as described previously [33,48]. Samples 
were prepared in sealed 384-well microplates (Greiner Bio-One, Kremsmünster, Austria) and 
incubated using a FLUOstar Optima microplate reader (BMG Lab Technologies, Melbourne, 
Australia), replicating the conditions of the ThT kinetic assays in the absence of ThT. Briefly, 
1.5 µL of sample at various time points during fibril formation were dotted onto nitrocellulose 
membranes and blocked with 5% skim milk in TBS-T at room temperature for 1 h. Membranes 
were washed four times prior to incubation with either an A11 anti-oligomer (1:5000 in 2% 
skim milk TBS-T) (Invitrogen, California, USA) or an anti-fibril (ab205339, 1:5000 in 2% skim 
milk TBS-T)) (Abcam, Cambridge, United Kingdom) at 4 °C overnight. An IgG-HRP secondary 
antibody (403001) and Clarity™ ECL substrate (both Bio-Rad, California, USA) were used for 
detection. The intensity of the blots was quantified using ImageJ [49], where experiments 
were performed in triplicate and data reported as mean ± SEM. Data was analysed by one-
way ANOVA using Prism 8.0 (GraphPad Software, La Jolla, USA). 
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 Ion-mobility mass spectrometry 
IM-MS analysis was performed on a Synapt HDMS G1 Q-TOF mass spectrometer (Waters 
Corporation, Manchester, UK) using a nano-electrospray ionisation source. Samples were 
prepared in 100 mM ammonium acetate (pH 7.0) to a final protein concentration of 50 μM. 
Aβ40 and αS were incubated in the presence of LUVs (1:10 molar ratio; protein:LUV) and/or 
inhibitor (1:1 molar ratio; protein:inhibitor) for 10 min at room temperature before analysis. 
Samples were loaded into platinum-coated borosilicate glass capillaries prepared in-house. 
Gentle ionisation and gas-phase conditions were applied to minimise structural changes prior 
to detection [50], with instrument parameters as follows: capillary voltage, 1.60 kV; sampling 
cone, 30 V; extraction cone, 1.5 V; trap/transfer collision energy, 10-15 V; trap gas, 5.5 l/h; 
backing gas, ∼4.5 mbar. The parameters for IM were as follows: IM cell wave height, 8 V; IM 
cell wave velocity, 350 m/s; transfer t-wave height, 8 V; transfer t-wave velocity, 250 m/s. 
Mass spectra and arrival time distributions (ATDs) were viewed using MassLynx (v4.1) and 
DriftScope (v2.1), respectively (Waters Corporation, Manchester, UK). 
 
3.4 Results 
 LUVs increase the rate of Aβ40 fibrillization and reduce EGCG-resveratrol efficacy 
The effects of LUVs consisting of either PC or PCPG on Aβ40 fibril formation were first 
assessed by performing ThT kinetic assays (Fig. 1). These aggregation assays were carried out 
in the presence of LUVs of certain size (i.e. 100 nm polycarbonate membranes were used to 
create homogenous LUVs) in order to prevent any influences on aggregation kinetics arising 
from differing vesicle sizes. The size distribution of the LUVs was confirmed by DLS (Supp. Fig. 
1) which displayed a normal and narrow size distribution with diameters of approximately 
100-300 nm. Furthermore, ThT experiments in the presence of LUVs alone were conducted 
to verify that the addition of lipids did not significantly affect ThT fluorescence properties 
(Supp. Fig. 2).  
Aβ40 showed an increase in ThT fluorescence in the plateau phase as well as an increased 
rate  of fibril elongation when incubated with both PC and PCPG LUVs (1:30 molar ratio, 
Aβ40:LUV), with PCPG LUVs elongating over six times faster compared to Aβ40 alone (Supp. 
Table 1). The formation of mature fibrils was confirmed by TEM (Fig. 1B) and interestingly, 
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Aβ40 fibrils incubated with LUVs appeared to be vesicle-bound (Fig. 1C and D), suggesting 
LUVs increase the fibrilization propensity of Aβ40 through interactions at the bilayer surface. 
 
Figure 1.  PC and PCPG LUVs alter the aggregation kinetics and fibril formation of Aβ40. (A) 
Aβ40 (50 µM) (blue) fibril formation was monitored by the change in ThT fluorescence in the 
presence of either PC (green) or PCPG (pink) LUVs (1:30, Aβ40:LUV). Data are reported as 
mean ± SEM (n = 3). TEM images show the morphology of Aβ40 alone (B) and in the presence 
of PC (C) and PCPG (D) LUVs at the same molar ratios. Scale bars represent 500 nm. 
 
Additional ThT assays were conducted to assess the efficacy of small molecule amyloid 
inhibitors while in the presence of LUVs. Resveratrol and EGCG are known fibril inhibitors 
broadly effective against a variety of amyloidogenic proteins. However, they have differing 
modes of inhibition and differing levels of efficacy [51]. EGCG and resveratrol were added at 
a 1:1 molar ratio  which has been used previously to assess inhibitory efficacy of these 
molecules [33,47]. Upon incubation with LUVs, both EGCG (Fig. 2A) and resveratrol (Fig. 2B) 
were found to be less effective as fibrilization inhibitors. Consistent with previous studies of 
Aβ40 [33,51], EGCG significantly limits ThT fluorescence at a 1:1 molar ratio, with a 95% 
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decrease in fluorescence at plateau compared to Aβ40 alone. However, when incubated with 
either LUV at a 1:30 ratio (Aβ40:LUV), the inhibitory efficacy of EGCG was reduced, with a 
plateau fluorescence decrease of 81% and 50% in the presence of PC and PCPG LUVs 
respectively (Fig. 2A and Supp. Table 1). Interestingly, Aβ40 in the presence of LUVs displayed 
a decrease in ThT fluorescence following approximately 7 and 15 hours of incubation for PCPG 
and PC respectively, indicative of decreased mature fibril formation. This observed loss in 
fluorescence may be attributed to LUV degradation during the assay [52] at which point EGCG 
is able to remodel mature fibrils into smaller, amorphous aggregates [32,53]. 
The efficacy of resveratrol as an inhibitor of Aβ40 aggregation was also examined in the 
presence of LUVs. Resveratrol is generally less effective at inhibiting Aβ40 fibril formation 
than EGCG, with greater ThT fluorescence observed at the same inhibitor concentration. 
Nevertheless, similar to EGCG, incubation with LUVs resulted in a further reduction in the 
inhibitory efficacy of resveratrol (Fig. 2B and Supp. Table 1). However, unlike EGCG, no 
difference was observed between the zwitterionic (PC) and anionic (PCPG) LUV systems, and 
no decline in fluorescence was observed over time. This latter point is consistent with the 
reported mechanism of action of resveratrol; despite being shown to remodel mature fibrils 
at high concentrations [53], resveratrol appears to cap fibril formation but is unable to 
disassemble fibrils [37]. Overall, the combined data demonstrate the ability of LUVs to reduce 
the efficacy of two well-known small molecule inhibitors of fibrilization. PCPG was found to 
affect Aβ40 aggregation and inhibitor efficacy more significantly, and anionic LUVs have also 
been shown in literature to have a greater affinity for Aβ40 [22,54]. For this reason, we chose 




Figure 2. Inhibiting Aβ40 fibril formation by EGCG and resveratrol is compromised by PC and 
PCPG LUVs. The effect of LUVs on Aβ40 fibrillar inhibition by (A) EGCG (50 µM) and (B) 
resveratrol (50 µM) was monitored through ThT fluorescence assays. Aβ40 (50 µM) was 
incubated with either inhibitor in the presence and absence of LUVs (1:30, Aβ40:LUV). (C) The 
extent of fibril inhibition afforded by EGCG and resveratrol with and without LUVs was 
calculated by comparing the ThT fluorescence maximum across each treatment. Data are 
reported as mean ± SEM (n = 3). 
 
 LUVs increase the rate of αS fibril elongation and reduce EGCG-resveratrol efficacy 
To investigate whether the effects of LUVs on fibrillar aggregation and inhibition by EGCG and 
resveratrol are consistent between protein systems, we also performed analogous ThT 
experiments using αS (Fig. 3). Compared to Aβ40, αS aggregates at a much slower rate and 
allows for in vitro kinetic analysis to be performed in the presence and absence of seed fibrils 
in a robust manner. This allows us to separately examine the inhibitory action of EGCG and 
resveratrol during primary nucleation and fibril elongation stages in the presence of LUVs. As 
observed for Aβ40, in the presence of PCPG LUVs, αS fibrils elongated faster (5 times greater 
rate) compared to αS alone during primary nucleation-mediated fibrilization (i.e. unseeded 
aggregation) (Fig. 3A). However, in the presence of seed fibrils (2.5% w/w), the rate of fibril 
elongation remained similar to αS alone (Fig. 3B). The data suggests that LUVs primarily 
modulate the rate of fibril elongation through alterations in monomeric or early oligomeric 
structures during the nucleation phase. 
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EGCG and resveratrol were subsequently introduced into these systems to ascertain whether 
the LUVs had similar effects on inhibitory efficacy against αS aggregation. In the unseeded 
assays, the inhibitory activity of resveratrol towards αS aggregation was completely nullified 
in the presence of PCPG LUVs (Fig. 3A and C), and in fact, αS fibrils with resveratrol and PCPG 
elongated faster than αS alone, despite the presence of inhibitor. The inhibitor efficacy of 
resveratrol was also greatly reduced in the seeded αS system (Fig. 3B and D), however the 
rate of elongation remained consistent across all inhibitor conditions. Contrastingly, EGCG 
was found to be far more effective as an inhibitor against both unseeded and seeded αS 
aggregation, displaying little ThT fluorescence in the presence of PCPG LUVs. 
 
Figure 3. PCPG LUVs modulate the inhibitory efficacy of EGCG and resveratrol during seeded 
and unseeded αS aggregation. The effect of PCPG LUVs on unseeded and seeded αS fibril 
formation in the presence of EGCG (50 µM) and resveratrol (50 µM) was monitored through 
ThT fluorescence assays. (A) Unseeded αS (150 µM) and (B) seeded αS (50 µM with 2.5% w/w 
seed fibrils) was incubated with inhibitors in the presence and absence of LUVs (1:30 αS:LUV). 
The concentration-dependent inhibition activity of EGCG and resveratrol against unseeded 
(C) and seeded (D) αS fibril formation with and without LUVs was calculated by comparing 
the ThT fluorescence maximum across each treatment. Data are reported as mean ± SEM (n 
= 3). 
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 LUVs and inhibitors differentially influence the distribution of protein aggregation 
states 
ThT assays are only able to provide insight into the fibril content during the aggregation 
process, which ignores important details regarding monomeric structure and oligomeric 
populations. For these reasons, we also carried out immunoblotting experiments to ensure 
ThT-derived data mirrored relative fibril content across treatments, as well as to gain insight 
into pre-fibrillar oligomeric populations. Aβ40 fibril-specific antibodies were first used to 
validate ThT fluorescence data, with the relative intensity (i.e. abundance) of fibrillar species 
compared to Aβ40 alone as a function of time (Supp. Fig. 3). In general, the relative 
abundance of fibrils present in the presence of LUVs and/or EGCG-resveratrol corresponds to 
the ThT kinetic data. 
We also performed immunoblotting to observe the abundance of pre-amyloid oligomers 
(using an A11 oligomer-specific antibody for both Aβ40 and αS) in the presence of LUVs and 
EGCG or resveratrol in order to gain additional mechanistic insight into their effects on early 
aggregation pathways (Fig. 4). The very short lag-phase of Aβ40 made discerning early 
oligomeric states difficult (Fig. 4A and 4B), however after 6 hours oligomeric abundances 
were observed to be lower in the presence of PCPG LUVs compared to Aβ40 alone. This may 
indicate that PCPG LUVs induce changes in oligomeric structure that are unrecognisable by 
anti-oligomeric antibodies, or alternatively, gives rise to faster aggregation leading to fewer 
oligomers present for antibody presentation (i.e. detection). Upon incubation with PCPG 
LUVs, αS showed a large increase in oligomer abundance in the early stages of fibril formation 
(after 24 hours, during the lag-phase). Then, similarly to Aβ40, a decrease in oligomer 
abundance was subsequently noted at 96 hours (Fig. 4C and 4D). Since the increase in 
oligomer abundance precedes the elongation-phase as shown by comparison with the 
unseeded αS ThT assay (Supp. Fig. 4), this suggests that PCPG LUVs increases oligomeric 
concentration and rapid fibril elongation. Interestingly, resveratrol increased the population 
of oligomers for both Aβ40 and αS when compared to the proteins in the presence of both 
resveratrol and PCPG. This is in contrast to Aβ40 and αS in the presence of EGCG, which 
showed lower oligomer formation compared to when incubated with both EGCG and PCPG, 
and further reinforces a different mechanism of action of the two inhibitors. 
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Figure 4. LUVs alter the abundance of αS and Aβ40 oligomers in the presence of EGCG and 
resveratrol during fibril formation. The effect of LUVs on oligomer formation during 
aggregation in the absence of presence of EGCG (50 µM) and resveratrol (50 µM) was 
observed by immunoblotting. (A) Aβ40 (50 µM) was incubated in the presence and absence 
of EGCG or resveratrol and LUVs (1:30, Aβ40:LUV) and the abundance of oligomers was 
quantified by densitometry (B). (C) αS (50 µM) was incubated in the presence and absence of 
EGCG or resveratrol and LUVs (1:30, αS:LUV) and the abundance of oligomers was quantified 
by densitometry (D). Data are reported as mean ± SEM (n = 3). 
 
 IM-MS reveals structural changes induced by EGCG complexes with Aβ40 and αS 
monomers 
Thus far, our data suggests that LUVs interact with amyloidogenic proteins early in the 
fibrilization pathway, potentially through changes in the structure of monomeric or low 
molecular weight oligomeric species. For this reason, we applied native IM-MS to interrogate 
structural features of soluble protein forms to provide further mechanistic insight into the 
combined effects of PCPG LUVs on aggregation and inhibition by EGCG and resveratrol. The 
nESI process gives rise to multiply charged protein ions, with the degree of protonation 
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dependent upon solvent-exposed surface area and hence protein foldedness [55]. In native 
IM-MS experiments, ions are separated not only based on their  m/z ratio, but also on 
rotationally averaged CCS values for a given charge state; the longer that ion takes to traverse 
the ion mobility sector, the larger its rotationally averaged CCS and vice versa. IM arrival time 
distributions can therefore be extracted from ion populations of a given m/z to provide 
structural information based on overall size.  
We first analysed any changes in the monomeric structure of Aβ40 due to the addition of 
EGCG, PCPG LUVs or both (Fig. 5A). EGCG and PCPG were primarily investigated here as they 
had the greatest effect on both inhibition and aggregation respectively, and resveratrol was 
not found to form stable complexes with either of the proteins (Supp. Fig 5). While PCPG 
showed little effect on the native Aβ40 mass spectrum, the addition of EGCG produced peaks 
corresponding to Aβ40:EGCG complexes with stoichiometries up to a Aβ40 1:3 EGCG ratio 
(Fig. 5A). However, in the presence of both EGCG and PCPG LUVs, only Aβ40 1:1 EGCG 
complexes were observed. This reduction in EGCG binding to Aβ40 potentially indicates a 
mechanism in which PCPG LUVs reduces EGCG inhibitor efficacy by inducing structural 
changes that decrease EGCG binding affinity. 
To better understand the overall structural transitions of Aβ40 under these varying 
conditions, the arrival time distribution (ATDs) for the major charge states were extracted and 
compared. In the presence of PCPG LUVs, Aβ40 monomers adopt a more compact structure 
(i.e. shorter drift times) when compared with Aβ40 alone (Fig. 5B), where significant ATD 
deviations were observed particularly at lower charge states. In contrast, Aβ40 in the 
presence of EGCG showed similar ATDs compared with Aβ40 alone, though with a notable 
reduction in ATD widths. This reduction in ATD width is indicative of a decrease in structural 
heterogeneity, as the protein samples fewer conformations during separation by IM. When 
Aβ40 was in the presence of both EGCG and PCPG we observed an apparent combination of 
effects, with an increase in more compact species as well as a decrease in ATD widths, most 
notable for the lower charge states (M3+).  
Following this general evaluation of the effects of PCPG and EGCG on Aβ40 structural  
heterogeneity, we analysed the ATDs of the M4+ (as the base peak in the spectra) more closely 
to interrogate changes to the monomeric structure of Aβ40 in detail (Fig. 5C). The M4+ ion of 
Aβ40 alone showed three main structural populations with drift times centred at 
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approximately 4.5 ms, 6 ms and 7 ms. No stable complexes were detected between Aβ40 and 
PC or PG lipids, and only small changes in monomeric structure were observed for the M4+ ion 
in the presence of PCPG LUVs. Following incubation with EGCG, only small structural changes 
in monomeric Aβ40 were observed, indicated by the disappearance of the most unfolded 
population at 7 ms and narrowing of the ATD, suggesting reduced heterogeneity. 
Analysis of the EGCG:Aβ40 complexes revealed more significant changes in the drift time of 
the M4+ ions.  For example, the 1:1 Aβ40:EGCG complex showed a large change from 
moderately compact structures with ATDs at approximately 6 ms towards more compact 
structures with an ATD centred at approximately 5 ms (Fig. 5C), as well as the appearance of 
a more compact ion population at 4 ms. This shift in structural compaction was most clear for 
the 2:1 EGCG:Aβ40 complex showing a total transition to species with ATDs between 4-5.5 
ms despite a large increase in mass (from a 4,330 Da monomer to a 5,247 Da complex). This 
implies that EGCG influences structural compaction upon binding, or is otherwise targeting 
more compact conformations for binding, which is consistent with previous observations by 
IM-MS and NMR [56,57]. Notably, an ATD feature centred at 7 ms was absent in the presence 
of EGCG but present when incubated with both EGCG and PCPG, along with a general 
broadening of the ATD. This suggests that PCPG restores the disordered state of Aβ40 
(heterogeneity), while also simultaneously influencing transitions toward more compact 
structures, thereby increasing its propensity for aggregation. The competing mechanisms of 




Figure 5. Native IM-MS unravels the structural heterogeneity of Aβ40 in the presence of 
EGCG and PCPG LUVs. (A) Native MS spectra of Aβ40 (50 µM) in the presence of PCPG (500 
µM) and/or EGCG (50 µM). Complexes with EGCG (1:1, 2:1 and 3:1, EGCG:Aβ40) are primarily 
observed from the M4+ charge state (A, inset). (B) Heat map comparisons of Aβ40 ATDs for 
each charge state. Aβ40 compared to Aβ40 + PCPG (C, left), Aβ40 compared to Aβ40 + EGCG 
(C, middle) and Aβ40 compared to Aβ40 + PCPG + EGCG. (C) ATD analysis of Aβ40 M4+ in the 
absence of EGCG, M4+ in the presence of EGCG (50 µM), M4+ 1:1 Aβ40:EGCG complex and M4+ 
1:2 Aβ40:EGCG complex. 
 
Analogous native IM-MS experiments were performed to evaluate the effects of EGCG and 
PCPG LUVs on αS. Much like for Aβ40, αS was shown to form EGCG:αS complexes up to a 3:1. 
However, unlike for Aβ40, 1:1 lipid:protein complexes were also observed at lower charge 
states (M7+ and M8+) under these conditions (Fig. 6A), although peak intensities were too 
small to obtain reliable ATDs or differentiate the identity of the lipid. Structural changes were 
then observed through shifts in ATDs when incubated with EGCG and PCPG, where extracted 
ATDs for each individual charge state were compared across the different conditions (Fig. 6B). 
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Overall, the ATD trends observed for αS were comparable with that of Aβ40. In the presence 
of PCPG LUVs, there was an increase in conformational heterogeneity and compaction as seen 
by the deviation in the heat maps towards lower drift times, which were most notable at 
lower charge states. The presence of EGCG induced αS to adopt little change in drift time 
except for a reduced peak intensity at 8 ms. Again, similarly to Aβ40, EGCG and PCPG LUVs 
induced ATD changes resembling a combination of effects from both EGCG and PCPG alone, 
although the EGCG effects seemed to slightly predominate which may hint at the greater 
inhibitory efficacy of EGCG toward αS fibrilization compared with Aβ40. 
The 11+ charge state of αS was analysed by IM-MS (Fig. 6C) as it had the best compromise 
between IM resolution and low charge, which is typically indicative of native-like structure 
[55]. The M11+ ions of αS showed two distinct populations with ATDs at 8.6 ms and 9.9 ms, 
with the latter feature exhibiting greater intensity. Upon incubation with PCPG LUVs, the 
distribution of the αS structural populations shifted, preferencing the more compact 
structures with ATDs centred on 8.6 ms, and an increase in structural heterogeneity was 
observed. A more compact structure is often associated with the transition to an aggregation-
prone state as the protein enters a lower energy, off-pathway structure prior to self-
association [58–60], and hence these observations may rationalise the increased aggregation 
propensity (Fig. 3A). Similarly to Aβ40, the data suggested EGCG preferences binding to more 
compact structures as the 1:1 αS:EGCG ATD was observed at 8.6 ms, a phenomenon which 
has been previously observed [57]. Since compaction has been noted as a phenomenon 
occurring before the fibrillar aggregation of amyloid proteins, the high efficacy of EGCG may 
be due to targeting this process through complexation [60–62]. A reduction in the abundance 
of EGCG-protein complexes was again observed in the presence of PCPG LUVs, which, along 
with the competing structural effects of the inhibitor and lipids, provides further basis for 




Figure 6. Native IM-MS examines the structural heterogeneity of αS in the presence of EGCG 
and PCPG LUVs (A) Native MS spectra of αS (50 µM) in the presence of PCPG (500 µM) and/or 
EGCG (50 µM). Complexes with EGCG (1:1, 2:1 EGCG:Aβ40) are primarily observed (A, inset). 
(B) Heatmap comparisons of αS ATDs for each charge state. αS vs αS + PCPG (C, left), αS vs αS 
+ EGCG (C, middle) and αS vs. αS + PCPG + EGCG. (C) ATD analysis of 11+ αS monomer in the 





Effects of the lipid membrane are vitally important considerations in the fibrillar aggregation 
process which have only gained recent attention and focus. Lipid binding is important for both 
Aβ40 and αS in their functional states. For example, amyloid precursor protein, the protein 
from which Aβ40 is derived through proteolysis, is a membrane bound protein [25,63] and αS 
is thought to play a role as a lipid vesicle tethering protein via an N-terminal double-anchor 
mechanism [64–66]. Many studies have suggested that lipid membranes initiate aggregation 
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of Aβ40 and αS, acting as a catalytic surfaces for misfolding and fibrilization [20,67,68]. Since 
potential small molecule inhibitors may be competing against this process, it is important to 
consider their activity in the lipid environment. On top of this, the aetiology of misfolding 
diseases is also thought to be due to membrane interactions of misfolding monomer and/or 
oligomers through disruption, permeation and lysis of neuronal membranes [11,12,69,70]. 
Therefore, a better understand of this interplay is important to lead to successful therapy 
design. Given that recent work has shown the effectiveness of EGCG as a fibril inhibitor is 
environment dependent, including considerations such as oxidation status and pH [71], we 
investigated how lipid environments may affect the efficacy of two well-known inhibitors of 
fibrillization, EGCG and resveratrol, towards Aβ40 and αS fibril formation.  
We have demonstrated that both PC and PCPG LUVs increase the rate of Aβ40 aggregation. 
However, this effect was more significant in the anionic lipid environment, supporting current 
opinions that suggest electrostatic effects play an important role in protein-lipid interactions 
and thereby have a more pronounced effect on aggregation propensity [18,22,72]. Similarly, 
LUVs increased the rate of αS fibril elongation by 8 times in the absence of preformed seed 
fibrils compared with a 1.1 times increase in elongation rate for seeded αS aggregation. This 
is consistent with a mechanism in which the lipids primarily influence aggregation in the 
nucleation phase through a pathway dependent on lipid composition and relative 
concentration of aggregating protein [20,26,73]. TEM data indicated LUVs were bound to 
fibrils, potentially due to elongating fibrils propagating from a localised protein concentration 
on the LUV surface. If electrostatic interactions increase the local concentration of protein on 
the LUV surface to a greater extent, this would explain the increased elongation rates in the 
presence of PCPG over PC LUVs, especially given that both Aβ40 and αS have been shown to 
interact with anionic LUVs preferentially [22,74,75].  
Importantly, we have also demonstrated that the lipid environment drastically reduces the 
ability of EGCG and resveratrol to prevent fibril formation in both Aβ40 and αS systems. 
Anionic PCPG LUVs again had a more significant effect than zwitterionic PC LUVs in the case 
of EGCG and Aβ40 aggregation, although both LUVs reduced resveratrol inhibition equally. 
These differences highlight the different inhibition mechanisms of EGCG and resveratrol, 
where EGCG inhibits in the nucleation phase and can remodel fibrils, while resveratrol caps 
fibrils early in the elongation phase [30–33,36–38].  
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Immunoblotting revealed the abundance of oligomeric αS was much higher just prior to 
elongation when in the presence of PCPG LUVs. Recent research has shown the highest 
energy barrier in fibril elongation is the transition from oligomer to immature fibrils, and the 
majority of these oligomers do not form fibrils [76]. A higher oligomer concentration would 
therefore be expected to increase the probability of oligomer to fibril transitions, denoting a 
mechanistic explanation for the increased elongation rate. Interestingly, oligomer abundance 
was higher in the presence of resveratrol alone than both resveratrol and PCPG, which was in 
contradiction to the analogous conditions with EGCG and PCPG. This suggests EGCG decreases 
oligomeric concentrations more effectively than resveratrol. The increased oligomeric 
concentrations due to PCPG LUVs may outpace the ability for resveratrol to effectively cap 
fibrils, leading to more fibril formation than PCPG with EGCG.  
Native MS revealed Aβ40 and αS formed complexes with EGCG while resveratrol did not, 
consistent with previous work [56,57]. However, the abundance of EGCG-protein complexes 
was notably reduced in the presence of lipid. In addition, native IM-MS data showed PCPG 
LUVs increased the extent of structural compaction across multiple charge states as well as 
increasing structural heterogeneity for both Aβ40 and αS. Compaction is a phenomenon 
previously suggested to initiate aggregation [60–62], while increased conformational 
heterogeneity is consistent with the formation of additional pre-amyloid states that provide 
greater probability for oligomer to fibril transitions [76]. In contrast, EGCG was shown to 
decrease the structural heterogeneity across charge states. If EGCG more specifically targets 
species early on the aggregation pathway (i.e. monomeric and smaller oligomeric species), it 
may intercept the mechanisms that increase nucleation as a result of the lipid environment. 
This may also explain why LUVs had a greater effect on resveratrol inhibition than EGCG, as 
resveratrol targets elongation more specifically and therefore cannot prevent the LUV effects 
[36,37]. 
In summary, we provide further evidence that lipid environments affect the structure and 
aggregation kinetics of amyloidogenic proteins, Aβ40 and αS, and add insight into inhibition 
mechanisms of EGCG and resveratrol in this environment. Importantly, LUVs appear to reduce 
the effects of these small molecule fibril inhibitors through competitive mechanisms affecting 
protein conformational states. In particular, the potent aggregation inhibitor EGCG complexes 
with monomers and reduces conformational heterogeneity while PCPG LUVs induce 
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structural compaction and increased heterogeneity of monomers for both Aβ40 and αS. 
Therefore, these opposing effects may explain a reduction in inhibition by LUVs. This study 
highlights the importance of the cellular membrane in the fibrillar aggregation of misfolded 
proteins, together with our relative lack of understanding on the structural effects that this 
environment induces on amyloid structure and dynamics. A lack of regard for the effects of 
the lipid environment during therapeutic design ultimately exemplifies how current 
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Supplementary Table 1. Rates and amyloid inhibition percentages derived from ThT assays 
(main text, Figures 1-3). All values except for seeded αS assays were derived from non-linear 
sigmoidal dose response models fit to relative maximum fluorescence. Seeded αS curves were 
fit with a one-phase exponential association model due to the lack of a lag phase. All assays 









Aβ40 0.994 0.0130 0.090 0.0167 
+ PC 1.42 0.0121 0.161 0.0496 
+ PCPG 1.93 0.00304 0.619 0.0275      
Aβ40 1.01 0.0128 0.118 0.00795 
Aβ40 + EGCG 0.0509 0.00294 0.354 0.0909 
PC + EGCG 0.186 0.00606 0.328 0.0954 
PCPG + EGCG 0.503 0.00755 0.546 0.172      
Aβ40 1.03 0.0687 0.0722 0.0366 
Aβ40 + resveratrol 0.290 0.00579 0.186 0.0669 
Aβ40 + PC + resveratrol 0.576 0.00420 0.400 0.0408 
Aβ40 + PCPG + 
resveratrol 
0.589 0.00310 0.803 0.082      
Unseeded 
    
αS 0.982 0.0451 0.0153 0.00151 
αS PCPG 1:30 1.06 0.00269 0.116 0.00634 
αS EGCG 1:1 0.0312 0.0037 0.264 0.419 
αS EGCG PCPG 1:30 0.0216 0.00444 0.387 0.253 
αS Res 1:1 0.647 0.180 0.0265 0.00661 
αS Res PCPG 1:30 1.00 0.0776 0.0912 0.00776      
Seeded 
    
αS 0.684 0.00628 0.162 0.00666 
αS PCPG 1:30 0.896 0.00988 0.198 0.0110 
αS EGCG 1:1 0 0 0 0 
αS EGCG PCPG 1:30 0 0 0 0 
αS Res 1:1 0.308 0.0262 0.119 0.0367 




Supplementary Figure 1. Dynamic light scattering was performed to ensure PC (top) and 
PCPG (bottom) LUVs were of a homogenous size. LUVs were characterised at a concentration 




Supplementary Figure 2. A ThT fluorescence assay was performed to ensure the addition of 
lipids did not affect the ThT fluorescence under the conditions of the assays. Aβ40 (50 µM), 
PC and PCPG were separately incubated with ThT (50 µM) as well as ThT alone. Data are 





Supplementary Figure 3. The effect of LUVs on fibril concentrations and fibril inhibition by 
EGCG (50 µM) and resveratrol (50 µM) was monitored through immuno-dot blot assays. (A) 
Aβ40 (50 µM) was incubated in the presence and absence of inhibitors and LUVs (1:30 
Aβ40:LUV). (B) The relative concentrations of Aβ40 fibrils were quantified using densitometry. 




Supplementary Figure 4. LUVs alter the abundance of αS oligomers and increase the rate of 
fibril elongation. The effect of LUVs on oligomer formation during aggregation was observed 
by immunoblotting and ThT fluorescence. αS (50 µM) was incubated in the presence and 
absence of LUVs (1:30, αS:LUV) and the abundance of oligomers was quantified by 
densitometry (circles). This data was compared with the effect of PCPG LUVs on unseeded αS 
fibril formation (150 µM) through ThT fluorescence assays in the presence and absence of 




Supplementary Figure 5. Native MS shows resveratrol forms no stable complexes with Aβ40 
or αS. (A) Native MS spectra of Aβ40 (50 µM) in the presence of resveratrol (50 µM). Aβ40 
complexes with resveratrol were not observed (A, inset). (B) Native MS spectra of αS (50 µM) 
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Cross-linking mass spectrometry is a rapidly emerging technique that gives information on 
protein structure and subunit architecture. Typically in such an experiment, chemical 
reagents covalently link protein sites together, which, when followed by proteolytic digestion 
and detection of linkage sites by mass spectrometry analysis, gives information on inter- and 
intra-protein contacts. While many cross-linking reagents are commercially available, the 
specific functionalities may not always satisfy the diverse chemical and analytical 
requirements best suited for a particular system or experiment of interest. Here we describe 
a modular synthetic protocol allowing customisation of reactive groups and spacer-arms,  
giving flexibility in linker design to enable the vast variety of potential protein cross-linking 
experiments. Implementing the general synthetic method allowed for the production of 8 
unique homo- and heterobifunctional cross-linkers, including 4 different reactive groups, 
positive- and negative-mode mass spectrometry cleavable spacer-arms and sites for post-
linkage derivatisation, for example with enrichment and identification tags. Optimisation and 
application of these reagents to model systems exemplifies the potential for this modular 
protocol to address some of the analytical challenges associated with protein structure 




The function of proteins is inherently tied to their three-dimensional structure and how they 
interact with other molecules. Consequently, the ongoing development of analytical methods 
to probe protein organisation is critical for advancements in structural biology. Many protein 
systems are not amenable to structure determination by traditional high-resolution 
techniques such as x-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy, due to inherent limitations of the methods. As a result, alternative low-
resolution approaches such as chemical cross-linking combined with mass spectrometry (XL-
MS) have emerged as powerful alternatives. XL-MS is a highly versatile tool to interrogate 
protein structure and map protein-protein binding interfaces.1 Unlike these traditional 
methods, XL-MS does not require a homogenous analyte structure and can give information 
on highly dynamic proteins. Only micrograms of sample is required and it can be performed 
both in vitro and in vivo,2,3 with either targeted or proteome wide applications.4–6 
In a standard XL-MS workflow, proteins are chemically ligated in their native state using small 
molecule cross-linkers and then enzymatically digested. The resultant peptide mixture is 
sequenced by liquid chromatography tandem MS (LC-MS/MS) to locate linkage sites. The 
simplest cross-linker design includes two reactive units separated by a spacer arm which allow 
the compound to covalently link amino acids, commonly at basic or sulfhydryl residues (Fig. 
1). For example N-hydroxysuccinimide (NHS), the most common reactive group, targets lysine 
or N-terminal residues, while maleimide reactive groups target cysteines.3,7 In the case of 
certain proteins, amino acids of the same type are scarce, leading to the development of 
heterobifunctional linkers such as N-(α-maleimidoacetoxy) succinimide ester (AMAS), a linker 
that combines NHS and maleimide reactive groups. Building upon the concept of 
heterobifunctional reagents, non-specific linkers combine a ‘standard reactive group’ with a 
photoreactive group, typically aryl azides or diazirines, capable of linking indiscriminately to 





Figure 1. An example of a simple, commercially available cross-linker, disuccinimidyl glutarate 
(DSG), comprised of a non-cleavable 5 carbon chain between two lysine reactive NHS 
residues. 
 
Following covalent cross-linking, as the length of the spacer arm is known, inter- and intra-
protein upper distance constraints can be defined through site specific localisation of the 
cross-links.3 These distance constraints allow for the interrogation of protein binding 
interfaces, intramolecular contacts and stoichiometry.8  Furthermore, while techniques like 
crystallography require rigid structures for accurate models to be constructed, XL-MS can also 
capture regions that exhibit structural differences between conformational states, and can 
give information on the rearrangements and  transient interactions of proteins which are 
often critical in controlling cellular processes.2,3 
Despite great advances in the field of XL-MS, analytical limitations remain. For example, due 
to low reaction efficiencies, unlinked peptides and ‘dead-end’ modifications, which have 
linked on one end and are hydrolysed on the other, significantly outnumber useful intra- and 
inter-protein cross-links. This has led to an increased interest in the introduction of 
enrichment tags capable of extracting modified peptides through a variety of common 
methods such as avidin-affinity or immobilised metal affinity chromatography.9–12 In addition, 
peptides joined with non-cleavable linkers are required to be analysed as covalent pairs, 
giving rise to more complex MS/MS data as fragmentation occurs simultaneously from both 
chains. This has spurred the development of cleavable spacer-arms capable of fragmenting 
under low energy gas phase activation regimes (such as collision induced dissociation, CID) 
during MS.13,14 Here, linked peptides initially fragment at the labile spacer-arm yielding a 
characteristic fragmentation pattern, distinguishing them from unlinked and dead-end linked 
peptides, and enabling the peptide pairs to be sequenced independently by MS3 analysis to 
more easily identify the residue specific site of modification.15 Finally, alternative strategies 
such as use of isotopically labelled linkers or linkers with reporter tag motifs which show 
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characteristic mass differences during MS analysis can improve linked peptide 
identification.16  
The structural diversity of proteins also creates unique challenges for each individual protein 
system. For example, only having access to relatively few reactive amino acids can conceal 
important linkage information. Differences in the amounts and types of available amino acids 
necessitates different linker reactivity, while larger distances between reactive groups may 
require different length spacer-arms. This has driven the development of new reactive groups 
like aromatic glyoxal cross-linkers (ArGOs), dihydrazide sulfoxide and 1,1’- 
carbonyldiimidazole, capable of reacting with arginine, acidic and hydroxyl amino acids, 
respectively.17–19 While the wealth of new cross-linker options is beneficial to the field, in 
most applications, these are typically confined to commercially available compounds that lack 
flexibility in terms of spacer-arm length and the analytical features described above. 
The ability to easily access a diverse range of cross-linking reagents with different reactivities, 
structures and properties would greatly expand the capabilities of XL-MS. This study describes 
the development of a modular synthetic strategy which allows for the straight forward 
production of cross-linkers that can incorporate various functionalities, including enrichment 
and fluorescent tags, varied length or CID-cleavable spacer-arms and hetero- or 
homobifunctional reactive groups, to enable researchers to readily adapt linker selection to 
the specific needs of the experiment or system of interest. We exemplify the synthetic utility 
of this strategy through construction of a small linker library and demonstrate application of 
the linkers to example peptide and protein systems. 
 
4.3 Results and Discussion 
 Development of a modular synthetic protocol 
To address the lack of diversity in commercially available cross-linker options, a modular 
synthetic protocol was developed based around amino acid building blocks to ensure the 
components are readily available, low cost and easily adaptable for functional group 
tuneability (Fig. 2). The synthesis was designed to allow for reactive groups and spacer arms 
that can be exchanged depending on the demands of the experiment, while also including a 
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motif to which enrichment or luminescent tags (or other functionalities) can be attached after 
cross-linking.  
 
Figure 2. (A) The general structure of the modular linker includes 3 components; the ‘click’ 
modified amino acid core (blue), the spacer arm (green) and the reactive group (red), which 
can be synthesised in a combinatorial fashion (B). (C) Structures contained in the cross-linker 
library synthesised using the modular protocol. 
 
At the core of the synthetic strategy is a base unit that includes a ‘click’ tag capable of 
undergoing derivatisation under biocompatible conditions. This click chemistry is mediated 
by an alkyne or azide tag which allows for the inclusion of post-linkage modifications via a 
copper catalysed Huisgen cycloaddition. Currently, there are numerous examples of 
alkyne/azide reagents that are commercially available, including modifications such as dyes, 
FLAG tags and agarose or magnetic beads. Two base units were proposed with an alkyne and 
an azide click tag (Fig. 2B), which allow for the same sample to be aliquoted and derivatised 
with more than one modification, which would be impossible if modifications were 
introduced to the linker prior to cross-linking. The alkyne base unit (12) was synthesised by 
O-alkylation of commercially available tert-butyloxycarbonyl-protected (N-Boc) serine with 
propargyl bromide, followed by a one pot N-Boc cleavage and methyl esterification (Supp. 
Scheme 1). The azide base unit (10) was synthesized by a diazo transfer reaction with an N-
Boc protected lysine, followed by the same one pot N-Boc cleavage and methyl esterification 
reaction (Supp. Scheme 1).  
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Following synthesis of the two base units, all subsequent reactions followed the same general 
reaction scheme wherein in the spacer-arm is coupled to the amino acid base unit by a 
peptide coupling, followed by a methyl ester hydrolysis and finally coupling of the reactive 
groups to the exposed acids (Scheme 1). For the easy incorporation of different spacer arms, 
the synthesis was designed around a hexafluorophosphate azabenzotriazole tetramethyl 
uronium (HATU) mediated peptide coupling so that any spacer arm with a carboxylic acid 
could be incorporated into the final compound (Fig. 2B). This allows different spacer arm 
lengths to be chosen by selecting the appropriate length diacid for coupling. In this study two 
examples were chosen, monomethyl adipate and heptanedioic acid, to showcase the 
simplicity by which different carbon chains lengths can be included.  
To demonstrate the incorporation of gas-phase labile bonds into the cross-linker spacer arm, 
two additional diacids were chosen for coupling; S-methyl 5,5′-thiodipentanoic acid, capable 
of fragmentation under low energy CID conditions in the positive ion mode20 and 3,3’-
dithiopropionic acid, capable of facile fragmentation under negative ion CID conditions.21. It 
is possible to perform XL-MS analysis under both positive and negative ion MS conditions, and 
therefore it is advantageous to incorporate moieties that undergo selective fragmentation in 
both of these modes. For linkers 4, 6 and 7 an additional step was necessary wherein the 
penultimate NHS-coupled compound undergoes methylation with methyl iodide to form the 
fixed charge sulfonium ion required for positive ion-mode fragmentation. 
Following peptide coupling of the spacer arm, alkaline hydrolysis of the methyl ester yields 
two free carboxylic acids with which a variety of reactive groups are available for EDC coupling 
to generate the final reactive linker. Further customisation is possible to introduce UV-
reactive heterobifunctional cross-linking through the coupling of 3-methyl-diazirine-3-
propanoic acid, instead of a diacid, to yield linker 8. Subsequent steps follow the same 
protocol, with the exception of reducing the equivalents of NHS coupling reagents to reflect 
that only one NHS is coupled to the final linker.  
Based on this general synthetic protocol, a small library of eight linkers was synthesised with 
differing spacer arm lengths, fragmentation moieties and reactive groups, all of which 
included an alkyne or azide tag available for further modification post-linkage (Fig. 2C).   
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Scheme 1. General synthetic protocol highlighting the modularity of the approach. 
Introducing a diacid (where X represents different spacer arm options) and reactive group of 
choice allows for synthesis of a custom linker.  
 
 
 Cross-linking and fragmentation characterisation 
To demonstrate the reactivity of the synthesised library, a selection of amine reactive linkers 
was applied to a test peptide, acetylated AAKA (AcAAKA), which is a simple model system 
with a single primary amine available for cross-linking. Incubation of cross-linkers with 
AcAAKA at a high concentration allows for the simulation of the peptide linkages that could 
be expected in a proteolytic digest. Initially, compound 1 was used to form a cross-link 
between AcAAKA peptides and MS/MS analysis was performed on the linker peptide 
complex, the structure of which was confirmed by the expected fragmentation products 
(Supp. Fig. 1). Following this, the facile fragmentation of CID cleavable linkers was validated 
using a negative and positive ion mode cleavable linker (compounds 3 and 4 respectively). 
Both compounds were reacted with AcAAKA and MS/MS analysis revealed spectra consistent 
with expected dissociation patterns (Fig. 2). Compound 4 formed a 6-membered oxazoline 
ring under low energy CID, preferencing the non-serine side, yielding a 125 m/z mass 
difference between fragmentation products (Fig. 3A).20 Capable instruments may then scan 
for this characteristic 125 m/z doublet during MS/MS under lower fragmentation energies 
and isolate each ion for higher energy MS sequencing experiments, allowing each linked 
peptide to be more easily identified and then sequenced, greatly improving site-specific 
localisation of the modification.22 Similarly, the negative ion mode linker cleaved as expected 
forming a characteristic quartet fragmentation pattern, also suited to subsequent MS3 
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sequencing experiments.23 The facile fragmentation about the disufide bond in the linker 
chain is effected by either an enolate anion or by an anion situated directly adjacent to the 
disulfide.24 There are therefore four potential products possible as fragmentation can take 
place on the serine or non-serine side of the disulphide bond, although the relative 
abundance of these signals in the MS/MS spectra of the linked AcAAKA peptides did not reveal 
significant preference for either side in this example (Fig. 3B).  
 
Figure 3. (A) Low CID energy of linker 3 cross-linked to AcAAKA yield two major daughter ions 
corresponding to 6-member oxazoline rings on the non-serine (484.27 m/z) or serine side 
(609.32 m/z) from the parent ion (1140.58 m/z). (B) The linker 4 parent ion (1100.51 m/z) 
yielded 4 daughter ions upon CID at a low energy: an enol product on the non-serine (454.24 
m/z) and serine (579.29 m/z) side and a thiol product on the non-serine (488.23 m/z) and 
serine (613.28 m/z). 
 
Overall, these results confirm that the alkyne modified serine is a suitable base unit to be 
combined with diacid spacer arms in order to successfully form covalent links between lysine 
residues, and the resultant linkers are able to effectively fragment under CID conditions. 
 
 Post cross-link derivatisation of the modular linker 
A feature of the modular linker design is the included alkyne/azide tag which can be 
derivatised subsequent to the reaction with proteins. This is advantageous since it avoids the 
inclusion of bulky groups such as biotin in the reactive linker, which can potentially restrict 
access to reactive sites on the protein during the cross-linking reaction. It also allows for 
flexibility in the choice of ‘clickable’ motif to include a range of functionalization. Alkyne and 
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azide groups on biotin, fluorescent tags, agarose UV-cleavable beads, peptides and oligos, 
amongst many other examples, are becoming increasingly available commercially, and the 
flexibility to apply several tags to a single cross-linked sample is attractive. After validation of 
covalent linkage, the ability for post-cross-linking derivatisation of the linkers through a 
copper catalysed Huisgen cycloaddition reaction was demonstrated with both biotin for 
enrichment and Cy3 for fluorescent visualisation. 
Following covalent linkage between compound 1 and AcAAKA, a simple copper catalysed click 
reaction facilitated the addition of biotin azide. Evidence for the successful derivatisation was 
provided by MS, with MS/MS analysis of the expected (M+H)+ ion of the product at 1294 m/z 
giving rise to expected fragmentation ions (Fig. 4A). Biotin affinity purification following this 
reaction allows for enrichment in a manner which is familiar and available to many 
biochemistry laboratories. 
The flexibility offered by post-cross-linking derivatisation was further showcased using two 
different linkers, compound 5 and 6. Both compounds and a commercially available control, 
disuccinimidyl sulfoxide (DSSO), were used to cross-link hen egg lysozyme and the resulting 
products were separated by SDS-PAGE and visualised using Coomassie Brilliant Blue stain (Fig 
4B). Modification of the lysozyme monomer by cross-linkers was confirmed by MS (Supp. Fig. 
2) with between 1 and 4 Linker 1 compounds covalently binding, whereas DSSO showed less 
dispersity with only 5 modifications. Despite differences in linker length that may affect lysine 
accessibilities, both custom linkers showed comparable cross-linking efficiency with the DSSO 
control, and dimer band densities were reflective of the monomer to dimer ratio in buffered 
solution.25 Before PAGE, a sample of protein linked with compounds 5 and 6 was further 
covalently modified with cy3-azide by copper catalysed cycloaddition, and modifications were 
evidenced by an upward band shift in the gel due to the added mass of the cy3 tag. The gels 
were then visualised by cy3 fluorescence emission at 556 nm, following excitation at 553 nm. 
To emphasize how fluorescence tags could be used to increase visibility of hidden covalently 
modified protein complexes, smaller amounts of cy3-modified proteins were loaded on the 
gel to reduce the dimer intensity below limits of detection of the Coomassie stain. (Fig 4B). 
Notably, the band width of lysozyme:cy3-linker complexes increased, giving an indication of 
heterogenous mass changes due to attached cy3 tags. Upon irradiation and fluorescence 
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detection, the dimeric species that were undetectable using Coomassie staining alone were 
revealed by the cy3 dye. 
 
Figure 4. (A) CID was used to characterise cross-linked AcAAKA using linker 1 followed by post-
linkage modification with biotin-azide using a Cu catalysed click cycloaddition reaction. The 
parent ion was identified (1293 m/z) and MS/MS analysis revealed characteristic fragment 
ions at 892 and 581 m/z that represent the parent ion minus one and two AcAAKA peptides, 
respectively. (B, left) SDS-PAGE revealed successful covalent linkage of lysozyme dimers using 
compounds 5 and 6 by comparison to a commercially available linker (DSSO), as well as post-
linkage modification with cy3 (B, right). Fluorescence imaging highlights the ability to uncover 
hidden oligomers through dye derivatisation of linked samples. 
 
The application of XL-MS has in recent years gone beyond in vitro samples and small numbers 
of interacting proteins, with cellular and tissue samples now subject to XL-MS for proteome 
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wide interactomic analysis. The avenue of in vivo cross-linking and the increased complexity 
of these samples has led to a greater dependence on enrichment tags and cleavable spacer-
arms. For example, cross-linking of mammalian cells with azide-A-DSBSO, a cross-linker 
capable of undergoing biotin click chemistry, was able to enrich and sequence 136 
intrasubunit and 104 intersubunit protein cross-links.26 Following this, new enrichment 
techniques allow for covalent linkage directly to alkyne or azide containing beads, skipping 
biotin-streptavidin enrichment techniques and improving enrichment efficiency by up to 5 
times.27 While impressive, the structural information obtained could be expanded upon 
further by introducing different spacer-arm lengths and reactive motifs using the modular 
approach presented. While this study explores 4 potential reactive groups, cysteine-reactive 
bismalemide and acid-reactive dihydrazide groups offer alternative linking chemistry that can 
be easily derived in one step from NHS-containing linkers as shown by Gutierrez, et al.7,18 
Furthermore, the wide availability of isotopically labelled amino acids would allow for the 
simple inclusion of a heavy serine/lysine base unit for synthesis, potentially yielding greater 
cross-link identification and even relative quantitation via the detection of characteristic 
isotope patterns during MS.16 
 
4.4 Conclusion 
This study presents a modular synthetic protocol for the synthesis of protein cross-linking 
reagents capable of tackling the individual challenges associated with protein structure 
determination by XL-MS. The ability to exchange reactive groups and spacer arms as needed 
was showcased through the synthesis of a library containing 8 unique cross-linkers. The 
reagents analysed here displayed covalent linkages with model peptides and lysozyme with a 
comparable efficiency to that of commercially available cross-linkers. The introduction of 
cleavable spacer arms allows for improved identification strategies through diagnostic 
fragmentation peaks. In addition, centring the synthesis around an alkyne-/azide-modified 
amino acid allows for introduction of additional functionality through copper click chemistry, 
as we demonstrated through post-linkage modification of biotin for avidin-affinity purification 
or cy3 for improved visualisation through fluorescence. Overall, this synthetic protocol aims 
to reduce the complexity of XL-MS by offering a scaffold for greatly improving the diversity of 
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potential cross-linking reagents, intentionally designed for the highly variable requirements 
of the field. 
 
4.5 Materials and methods 
 Materials and reagents 
Chemicals were purchased from Merck (Kenilworth, NJ, U.S.A.) or AK Scientific (Union City, 
CA, U.S.A.). The peptide AcAAKA was synthesised in-house using standard Fmoc solid-phase 
methods on 2-chlorotrityl chloride resin (GL Biochem, Shanghai, China) and purified by high-
performance liquid chromatography (HPLC) to greater than 95% purity as described 
previously.24 
 Synthesis of cross-linkers 
All linkers were synthesised from a general synthetic procedure beginning with amide 
coupling between the desired diacid spacer arm (this includes coupling with 3-methyl-
diazirine-3-propanoic acid) and either the alkyne base unit (12) or the azide base unit (10), 
followed by deprotection by methyl ester hydrolysis. Finally, esterification with N-
hydroxysuccinimide (NHS), tetrafluorophnenol (TFP) or pentafluorophenol (PFP) and EDC-HCl 
yielded the final linkers (Fig. 1C). 500 MHz 1H and 13C nuclear magnetic resonance (NMR) 
spectra were obtained using an Agilent 500/54 Premium Shielded NMR spectrometer (Agilent 
Technologies, Santa Clara, CA, U.S.A.). High-resolution mass spectrometry (HRMS) data were 
obtained using an Agilent 6230 TOF LC/MS equipped with an Infinity 1260 LC system (Agilent 
Technologies). MSMS data were obtained using a Micromass QTOF2 mass spectrometer 
(Milford, MA, U.S.A.). 
 Synthesis of compound 10 
Triflic anhydride (25 mL, 146 mmol) was added to a solution of sodium azide (26.6 g, 410 
mmol) in water (100 mL) while stirring at 0 °C. The reaction was allowed to warm to room 
temperature while stirring for 2 h, then extracted with dichloromethane (2 x 50 mL) and the 
combined organic extracts washed with saturated Na2CO3 (100 mL). The organic extract was 
added dropwise to a stirred solution of N-α-Boc-L-lysine (10.1 g, 41.1 mmol), CuSO4.5H2O 
(1.11 g, 4.45 mmol) and K2CO3 (8.68 g, 62.8 mmol) in 2:1 (v/v) methanol/water (450 mL) at 0 
°C. The solvent was removed under reduced pressure and the resulting residue diluted with 
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water (75 mL) and acidified by dropwise addition of 6 N HCl until the formation of a 
precipitate. The suspension was then diluted with potassium phosphate buffer (pH 6.2, 150 
mL of 1:1 (v/v) 0.25 M K2HPO4/ 0.25 M KH2PO4) before further acidifying to pH 3 with 6 N HCl. 
The mixture was then extracted with ethyl acetate (2 x 150 mL). The combined organic extract 
was washed with water (100 mL) and brine (100 mL), then dried (NaSO4) and the solvent 
removed under reduced pressure. The residue was dissolved chloroform (100 mL), filtered by 
suction filtration and the solvent removed under reduced pressure to obtain a yellow oil (10.4 
g, 93%). 
1H NMR (500 MHz, CD3OD, δ): 4.11-4.08 (q, J = 0.1 Hz, 1H), 3.33-3.30 (m, 2H), 1.88-1.81 (m, 
1H), 1.72-1.64 (m, 1H), 1.65-1.60 (q, J = 0.2 Hz, 2H),  1.54-1.47 (m, 2H), 1.46 (s, 9H). 13C NMR 
(125 MHz, CD3OD, δ): 176.2, 158.1, 80.5, 79.4, 54.7, 52.2, 32.4, 29.4, 28.7, 24.1. HRMS (ESI) 
m/z: [M+H]+ calculated for C7H14N4O2, 186.1117; found 188.1220. 
 Synthesis of compound 12 
Compound 12 was synthesised by dissolving Boc-L-Serine (2.01 g, 9.8 mmol) in DMF (100 mL) 
and stirring on ice for 15 min. A 60 % wt/wt dispersion of sodium hydride (995 mg, 24.8 mmol) 
was added and the solution was stirred on ice for 45 min. The reaction mixture was allowed 
to warm to room temperature and then stir overnight under a nitrogen atmosphere. Water 
(15 mL) was added and stirred for 5 minutes. The solution was washed with diethyl ether, 
acidified to <3 pH with 1 M KHSO4 and then extracted with ethyl acetate (3x 30 mL). The 
combined extracts were washed with water and dried over Na2SO4. The solvent was removed 
in vacuo to yield 11 as a yellow oil which was used without further purification (2.1 g, 91 %). 
1H NMR (500 MHz, DMSO-d6, δ): 5.38 (d, J = 8.2 Hz, 1H), 4.49 (d, J = 8.1 Hz, 1H), 4.23-4.14 (m, 
2H), 4.00 (dd, J = 8.8, 2.2 Hz, 1H), 3.81 (dd, J = 9.4, 3.5 Hz, 1H), 2.47 (t, J = 2.3 Hz, 1H), 1.46 (s, 
9H). 13C NMR (125 MHz, CDCl3, δ): 175.1, 155.9, 80.6, 78.8, 75.4, 69.6, 58.8, 53.8, 28.41. All 
NMR data is consistent with literature.28 
The acid (11) (2.00 g, 8.22 mmol) was dissolved in methanol (100 mL) and stirred on ice for 
15 min. Thionyl chloride was then added dropwise (1.20 mL, 16.4 mmol) under a nitrogen 
atmosphere. The solvent was removed in vacuo and the residue was co-evaporated with 
methanol three times to yield compound 12 (1.64 g, 97 %) as an orange oil. 
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1H NMR (500 MHz, DMSO-d6, δ): 8.64 (br s, 3H), 4.37 (t, J = 3.3 Hz, 1H), 4.24 (dd, J = 16.1, 2.2 
Hz, 1H), 4.20 (dd, J = 16.1, 2.2 Hz, 1H), 3.91 (dd, J = 10.5, 4.1 Hz, 1H), 3.85 (dd, J = 10.6, 3.0 Hz, 
1H), 3.76 (s, 3H) 3.56 (t, J = 2.1 Hz, 1H). 13C NMR (125 MHz, CD3OD, δ): 168.7, 79.4, 77.2, 67.6, 
59.4, 54.3, 53.9. All NMR data is consistent with literature.29 
HRMS (ESI+) calculated for C7H11NO3 [M+H]+ = 157.0739, found [M+H]+: 158.0359 
 General modular synthetic protocol 
10 or 12 was dissolved in dry tetrahydrofuran (THF) (5 mL per 100 mg) with 
diisopropylethylamine (4.0 mol eq) while stirring. The desired spacer arm diacid (1.0 mol eq) 
was added to the solution followed by HATU (1.2 mol eq). The mixture was stirred overnight 
at room temperature under a nitrogen atmosphere. 1 M HCl (5 mL per 100 mg) was added 
and the solution was extracted with ethyl acetate (1.5 mL per 100 mg, 3×). The organic phase 
was washed with water (3×) and brine then dried over Na2SO4 and the solvent was removed 
in vacuo. The product was then purified by flash chromatography on normal phase silica to 
yield the desired amide. 
To hydrolyse the methyl ester, the amide was dissolved in THF (1 mL per 100 mg) and stirred 
on ice for 15 minutes. 1 M LiOH (4 mol eq.) was added and the reaction was stirred until 
completion as determined by thin layer chromatography. The solvent was removed in vacuo 
and the residue was partitioned between DCM and water. The organic layer was isolated and 
the aqueous layer was extracted with DCM (2×). The combined organic extracts were washed 
with brine and dried over Na2SO4. The solvent was removed in vacuo to yield the desired 
diacid as a yellow oil. 
The diacid was dissolved in anhydrous THF (10 mL per 100 mg) with EDC-HCl (3.4 mol eq) and 
stirred at room temperature for 10 minutes. NHS, TFP or PFP (6 eq.) were added and the 
reaction was stirred at room temperature under a nitrogen atmosphere overnight. The 
solvent was removed in vacuo and the resulting residue was partitioned between DCM and 
water. The aqueous layer was extracted with DCM (3x) and the combined organic extracts 
were dried over MgSO4 and filtered. The solvent was removed from the filtrate in vacuo to 
afford the ester, which was used for cross-linking reactions without further purification. 
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 Synthesis of compound 4, 6 and 7 
Synthesis of positive mode cleavable linkers were based on work by Lu, et al.20 Following 
coupling with 5,5’-thiodipentanoic acid and the corresponding reactive group, the thioether 
was dissolved with methyl iodide (2.2 eq.) in dry acetonitrile (1.5 mL) and allowed to react 
while stirring at room temperature for 4 days. The solvent was then removed in vacuo yielding 
a yellow oil which was used for cross-linking reactions without further purification. 
 Cross-linking of AcAAKA 
Each linker was dissolved in DMSO to 10 mM with AcAAKA in a 1:1 linker:peptide ratio with 1 
eq. of diisopropylethylamine. The mixture was incubated at room temperature for 1 hour. 
The mixture was then diluted to 10 µM in 50:50 water:acetonitrile for analysis by negative 
ion mode tandem MS and with 0.1 % aqueous formic acid for analysis by positive ion mode 
tandem MS.  
 Cross-linking of hen egg lysozyme 
Lysozyme was dissolved in PBS to a concentration of 1 mg/mL. The relevant cross-linker was 
dissolved in DMSO (10 mM) and added to lysozyme solution at a ratio of 20:1 linker:lysozyme 
ratio. Protein was used for SDS-PAGE immediately or was buffer exchanged into ammonium 
acetate (100 mM) using a 10 kDa MWCO Amicon Ultra-0.5 Centrifugal Filter Device (Millipore, 
Jaffrey, NH, U.S.A.). 
 Copper click reaction 
The general procedure for CuAAC reactions was performed using a method adapted from a 
protocol available from Broadpharm.30 Peptide/protein conjugated with azide/alkyne linker 
(1mg/mL, 20 μL) was diluted with PBS (90 μL), followed by addition of aqueous solutions of 
2.5 mM biotin-azide (20 μL) or 2.5 mM Cy3-azide, 100 mM tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (BTTAA, 10 μL) (Click Chemistry Tools, Scottsdale, U.S.A.), 20 mM copper 
sulfate (10 μL) and 300 mM sodium ascorbate (10 μL).The reaction was incubated at room 
temperature for 30 min, then purified and concentrated into PBS (100 μL) using a 10 kDA 
MWCO Amicon Ultra-0.5 Centrifugal Filter Device. 
 SDS–polyacrylamide gel electrophoresis 
Lysozyme was cross-linked and examined by SDS–PAGE (12% gels) (Bio-rad, Hercules, CA, 
U.S.A.). Bands were visualised using Coomassie Brilliant Blue stain (ThermoFisher, Waltham, 
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MA, U.S.A.) according to the manufacturer’s instructions. Fluorescence imaging was 
performed on a ChemiDoc gel imagine system (Bio-rad, Hercules, CA, U.S.A.) using an 
excitation wavelength of 553 nm and emission was measured at 556 nm.  
 Matrix-assisted  laser  desorption  ionization mass spectrometry 
Matrix-assisted laser desorption/ionization (MALDI) spectra were acquired using an 
ultraFlextreme MALDI-TOF/TOF mass spectrometer in reflector positive mode, controlled by 
FlexControl softwarev3.4 (Bruker Daltonics). Protein samples were prepared for MALDI-MS 
analysis by mixing with an equal volume of 10 mg/mL α-cyano-4-hydroxycinnamic acid (HCCA) 
matrix in 70 % acetonitrile plus 1 % trifluoroacetic acid (TFA). This solution was deposited on 
a ground steel 384 target plate for analysis of intact proteins. Spectra were converted to 
mzXML file format using FlexAnalysis v3.4 (Bruker Daltonics, Billerica, MA U.S.A.), then 
processed, including smoothing, cropping and baseline subtraction, using mMassv5.5.0 
(http://www.mmass.org/).31 
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4.10 Supplementary Information 





Supplemetary Figure 1. MS/MS analysis of AcAAKA peptide cross-linked by compound 1 (m/z 





Supplementary Figure 2. MALDI spectrum shows doubly charged (approximately 7100 m/z) 
and singly charged (14,200 m/z) lysozyme. The protein is modified, increasing its mass, upon 
the covalent linkage with multiple cross-linkers. Dotted lines indicate additional modifications 









1H NMR (500 MHz, CDCl3): δ 6.39 (d, J = 8.0 Hz, 1H), 4.46 (dt, J = 8.0, 5.4 Hz, 1H), 3.62 (s, 3H), 
3.16 (dt, J = 6.7, 1.2 Hz, 2H), 2.08 (t, J = 7.5 Hz, 2H), 1.78-1.69 (m, 1H), 1.65-1.51 (m, 2H), 1.48 
(m, 4H), 1.36-1.26 (m, 2H), 1.26-1.21 (m, 2H), 1.09-1.02 (m, 2H), 0.87 (s, 3H) ppm. 
13C NMR: (125 MHz, CDCl3): δ 175.6, 174.9, 55.1, 54.4, 53.7, 38.8, 36.6, 34.7, 31.0, 28.3, 27.6, 




1H NMR (500 MHz, CDCl3): δ 9.95 (br s, 1H), 6.49 (d, J = 7.4 Hz, 1H), 4.54 (m, 1H), 3.24 (t, J  = 
6.8 Hz, 2H), 2.19 (t, J = 7.5 Hz, 2H), 1.90-1.84 (m, 1H), 1.72-1.69 (m, 1H), 1.62-1.54 (m, 4H), 
1.43-1.38 (m, 2H), 1.33-1.30 (m, 2H), 1.16-1.10 (m, 2H), 0.94 (s, 3H) ppm. 
13C NMR: (125 MHz, CDCl3): δ 177.8, 176.5, 54.7, 53.7, 38.7, 36.5, 34.2, 31.0, 28.4, 27.7, 26.1, 




(S)-perfluorophenyl 6-azido-2-(5-(3-methyl-3H-diazirin-3-yl)pentanamido)hexanoate (8) 
 




1H NMR (500 MHz, CDCl3, δ): 6.29 (d, J = 7.9 Hz, 1H), 4.79 (dt, J = 8.1, 3.1 Hz, 1H), 4.15 (dd, 
2H), 3.97 (dd, J = 9.4, 3.1 Hz, 1H), 3.82 – 3.74 (m, 4H), 3.67 (s, 3H), 2.46 (t, J = 2.4 Hz, 1H), 2.34 
(t, J = 6.9 Hz, 2H), 2.28 (t, J = 6.4 Hz, 2H), 1.75 – 1.61 (m, 4H). 
13C NMR (125 MHz, CDCl3, δ): 174.0, 172.5, 170.7, 79.0, 75.3, 69.6, 58.7, 52.8, 52.4, 51.7, 36.1, 




1H NMR (500 MHz, CD3OD, δ): 4.63 (t, J = 4.2 Hz, 1H), 4.18 (d, J = 2.4 Hz, 2H), 3.91 (dd, J = 9.6, 
5.0 Hz, 1H), 3.79 (dd, J = 9.6, 3.6 Hz, 1H), 2.86 (t, J = 2.4 Hz, 1H), 2.31 (q, J = 7.0 Hz, 4H), 1.71 
– 1.59 (m, 4H). 










1H NMR (500 MHz, CD3OD, δ): 4.71 (dt, J = 5.1, 3.7 Hz, 1H), 4.22 (dd, J = 2.4, 0.8 Hz, 2H), 3.95 
(dd, J = 9.7, 5.1 Hz, 1H), 3.81 (dd, J = 9.7, 3.8 Hz, 1H), 3.78 (s, 3H), 2.92 (t, J = 2.4 Hz, 1H), 2.33 
(q, J = 7.4 Hz, 4H), 1.74 – 1.62 (m, 4H), 1.48 – 1.35 (m, 2H) 
13C NMR (125 MHz, CD3OD, δ): 178.7, 177.5, 173.1, 81.3, 77.6, 71.3, 60.4, 55.2, 54.1, 37.6, 





1H NMR (500 MHz, CD3OD, δ): 4.64 (dt, J = 5.0, 3.6 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.92 (dd, J 
= 9.6, 5.0 Hz, 1H), 3.80 (dd, J = 9.6, 3.7 Hz, 1H), 2.87 (t, J = 2.4 Hz, 1H), 2.30 (td, J = 7.5, 3.7 Hz, 
4H), 1.92 – 1.83 (m, 4H), 1.64 (dp, J = 11.8, 7.5 Hz, 2H) 
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13C NMR (125 MHz, CD3OD, δ): 178.8, 177.4, 174.3, 81.4, 77.6, 71.5, 60.5, 55.1, 37.7, 36.0, 










1H NMR (500 MHz, CD3OD, δ): 4.71 (dt, J = 5.1, 3.7 Hz, 1H), 4.22 (dd, J = 2.4, 0.8 Hz, 2H), 3.95 
(dd, J = 9.7, 5.1 Hz, 1H), 3.81 (dd, J = 9.7, 3.8 Hz, 1H), 3.78 (s, 3H), 2.92 (t, J = 2.4 Hz, 1H), 2.33 
(q, J = 7.4 Hz, 4H), 1.74 – 1.62 (m, 4H), 1.48 – 1.35 (m, 2H) 
13C NMR (125 MHz, CD3OD, δ): 178.7, 177.5, 173.1, 81.3, 77.6, 71.3, 60.4, 55.2, 54.1, 37.6, 









1H NMR (500 MHz, CD3OD, δ): 4.66 (t, J = 4.2, 4.2 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.94 (dd, J = 
9.7, 4.8 Hz, 1H), 3.80 (dt, J = 9.8, 2.8 Hz, 1H), 3.01 – 2.90 (m, 4H), 2.72 (tt, J = 7.0, 3.2 Hz, 4H). 










1H NMR (500 MHz, CDCl3, δ): 11.29 (s br, 1H), 2.59 – 2.51 (m, 2H), 2.38 (t, J = 7.1 Hz, 2H), 1.80 
– 1.62 (m, 4H), 1.36 (td, J = 7.9, 1.1 Hz, 1H). 







1H NMR (500 MHz, CDCl3, δ): 2.54 (t, J = 7.2 Hz, 4H), 2.40 (t, J = 7.2 Hz, 4H), 1.80 – 1.61 (m, 
8H). 
13C NMR (125 MHz, CDCl3, δ): 177.46, 36.02, 30.88, 27.00, 22.09. 





1H NMR (500 MHz, CD3OD, δ): 4.67 (dt, J = 3.60, 1.37 Hz, 1H), 4.18 (d, J = 2.4 Hz, 2H), 3.92 (dd, 
J = 9.7, 5.0 Hz, 1H), 3.77 (dd, J = 9.7, 3.8 Hz, 1H), 3.74 (s, 3H), 2.89 (t, J = 2.4 Hz, 1H), 2.59 – 
2.51 (m, 4H), 2.31 (q, J = 7.3 Hz, 4H), 1.78 – 1.57 (m, 8H). 
13C NMR (125 MHz, CD3OD, δ): 178.3, 176.3, 175.9, 83.1, 81.5, 72.6, 61.7, 55.9, 55.9, 38.2, 












1H NMR (500 MHz, CD3OD, δ): 4.63 (t, J = 4.3 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.91 (dd, J = 9.6, 
5.0 Hz, 1H), 3.80 (dd, J = 9.6, 3.6 Hz, 1H), 2.87 (t, J = 2.5 Hz, 1H), 2.54 (t, J = 7.1 Hz, 4H), 2.31 
(q, J = 6.8 Hz, 4H), 1.78 – 1.66 (m, 4H), 1.63 (ddt, J = 12.1, 7.7, 5.0 Hz, 4H). 
13C NMR (125 MHz, CD3OD, δ): 178.3, 176.1, 175.4, 83.8, 81.5, 73.0, 61.7, 55.9, 38.3, 37.1, 
34.6, 34.6, 32.5, 32.5, 28.4, 27.6. 
 
(5-(((S)-1-((2,5-dioxopyrrolidin-1-yl)oxy)-1-oxo-3-(prop-2-yn-1-yloxy)propan-2-yl)amino)-5-
oxopentyl)(5-((2,5-dioxopyrrolidin-1-yl)oxy)-5-oxopentyl)(methyl)sulfonium iodide (4) 
 
HRMS (ES+) calculated for C25H34N3O10S [M]+ = 568.1959, found [M]+: 568.2037 
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Chapter 5: Towards the development of a modular synthetic route for 
protein chemical cross-linking reagents 
5.1 Introduction 
During the conception and design of the synthetic strategy and production of resulting 
crosslinking reagents described in Chapter 4, a considerable amount of work was conducted 
that did not comprise the end product compiled for publication. This includes a range of 
additional reaction steps, alternative reactions and partially synthesised products, as well as 
additional linker reagents that were not  included in the final manuscript. For this reason, this 
chapter serves as an supplement to discuss the broader synthetic approach and decisions 
made during the development of the synthetic procedure described in Chapter 4. 
 
5.2 Development of a modular synthetic protocol 
 Linker design 
To address the challenges associated with XL-MS, a synthetic route was designed that enabled 
the inclusion of different reactive groups, spacer-arms and affinity tags depending on the 
requirements of the experiment. Initially, the general linker design (Fig. 1) included NHS 
reactive groups, an exchangeable spacer-arm and an alkyne tag through which enrichment or 
post-linking functionalisation motifs could be introduced by 1,3 cycloaddition chemistry. 
 
Figure 1: The general proposed cross-linker includes a reactive group (green), spacer arm 
(blue) and an alkyne unit with which affinity tags can be ‘clicked’ on through a Cu catalysed 
cycloaddition reaction. X represents different spacer arm options. 
 
Retrosynthetic analysis of the general crosslinker devised in Chapter 4, 15, was performed to 
explore synthetic routes toward synthesis (Fig. 2). The formation of 15 can be achieved by 
activating the carboxylic acid acids of a diacid, 14, in the presence of NHS. The methyl diester, 
130 
13, can be formed through HATU-mediated peptide coupling between 12 and a methyl 
ester/acid, the length or composition of the carbon chain allows for tunability of the final 
spacer-arm component of the linker. Coupling 13 with a methyl ester/acid, rather than a 
diacid, ensures no di-addition side products are formed wherein 12 reacts on either side of 
the acid, as well as forming a diester 13 which reduces the compound polarity, making it 
easier to purify as the conjugate base can interact with the silica. N-Boc-protected serine is a 
cheap and commercially available amino acid, already protected for an O-alkylation with 
propargyl bromide to form 11, that can in turn yield 12 with a one-pot thionyl chloride (SOCl2) 
esterification, simultaneously deprotecting the amine and forming the methyl ester. 12 serves 
as the base unit for subsequent reactions with which different spacer arms can be attached.  
 
Figure 2: Retrosynthetic analysis of the proposed general linker. 
 
Previous work centred around applications with a monomethyl adipate based spacer arm 
failed to yield the final product, linker 1 (described in Chapter 4), in a useful amount and only 
small quantities were detectable by MS.1 To develop a modular synthetic protocol it was 
important to establish a synthetic route that was flexible enough to handle a variety of 
differing linker components with varied chemistries that may present challenges during 
synthesis. The work described here provides context for approaches that were trialled to 
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overcome the synthetic challenges of previous work and develop an adaptable synthetic 
route to create a cross-linker library that could be applied to biological samples. 
 
5.3 Development of the synthetic route 
To begin, a simpler spacer arm was applied to probe for issues in the synthetic procedure that 
were encountered in previous work.1 Retrosynthetic analysis revealed that an amide coupling 
with succinic anhydride would yield a two-carbon length spacer arm with which NHS 
esterification conditions could be trialled (Fig. 3). 
 
Figure 3: Retrosynthetic analysis of linker 1a. 
 
 Synthesis of succinimide linker 
Initially, development of the synthetic protocol began by trialling synthesis of a simple linker 
which incorporated a succinimide spacer-arm. Synthesis of the succinimide linker (Scheme 1) 
successfully yielded the corresponding diacid but EDC coupling with NHS failed. Analysis by 
MS failed to produce the expect m/z and crude NMR showed no sign of the characteristic 8H 
singlet at approximately 2.7 ppm. This was consistent with previous work that described 
issues with the total synthesis of the cross-linker pertaining to the NHS esterification 
reaction.1 To combat this, another reaction described by Rao, et al.2 was trialled, using 
activated NHS in the form of trifluoroacetic acid-NHS (TFA-NHS) and pyridine to deprotonate 
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the acids for esterification. Unfortunately, this reaction too reaction yielded no product 
following MS and NMR analysis. 
 
Scheme 1. Synthesis of succinimide linker 
  
 
 Synthesis of linker 1 
Observing incomplete NHS esterification of the succinic anhydride-based linker, it was 
proposed that the length of the carbon chain may be too short, with the steric bulk of the 
serine-alkyne motif interfering with the NHS esterification reaction. For this reason, synthesis 
of a linker with a longer carbon chain was attempted. Replacing succinic anhydride with 
monomethyl adipate as the spacer arm would increase its length by two carbons, potentially 
creating space enough between the acids to allow for successful synthesis. Aside from being 
inexpensive and commercially available, monomethyl adipate also yields a di-methyl ester 
following HATU-mediated peptide coupling (Scheme 2), meaning a second esterification is 
not necessary in comparison with succinic anhydride. This synthesis successfully yielded linker 




Scheme 2. Synthesis of linker 1
 
 
 Synthesis of linker 2 
Central to the proposed modular synthetic protocol is the ability to exchange spacer-arms to 
enable crosslinking reactions between protein sidechains that are further apart. Following the 
successful synthesis of linker 1, a linker of a longer length was attempted using heptanedioic 
acid as a spacer-arm (Scheme 3). The synthesis followed the same procedure as described for 
linker 1 with the exception that, following the HATU coupling, the resultant amide was not 
protected by another methyl esterification and instead was purified with 50:50 
EtOAc:petroleum ether with 0.1 % acetic acid to ensure protonation of the free acid. This 
allowed for successful separation of the product. Following ester hydrolysis, linker 2 was 
synthesised by coupling of NHS with EDC. 




5.4 Incorporation of a CID-cleavable spacer arm 
Cross-linkers capable of CID-induced cleavage in both positive and negative ion mode were 
designed for synthesis. MS is capable of ionisation in both positive and negative modes. For 
this reason cross-linkers capable of labile fragmentation in both polarities were considered 
for design. Dithiobis(succinimidyl) propionate (DSP)3 is a commercially available, negative-ion 
cleavable cross-linker that can be retrosynthetically broken down into NHS and 3,3’-
dithiopropionic acid. The disulphide spacer arm is capable of fragmentation when negative 
ionisation forms either an enolate anion, or an anion situated directly adjacent the 
disulphide.4 A characteristic, quartet fragmentation pattern is formed by each product, with 
spaces of 2 Da between the disulphide fragments and 66 Da between the enolate/disulphide 
fragments (Fig. 4).4 Disuccinimidyl sulfoxide (DSSO)5 and S-methyl 5,5’-
thiodipentanoylhydroxysuccinimide6 are positive-ion cleavable linkers that can be broken 
down to NHS and diacids by retrosynthetic analysis. DSSO rearranges upon protonation to 
form a characteristic doublet with a space of 50 Da, as the C-S bond is broken forming an enol 
and hydroxythio product. Upon protonation, S-methyl 5,5’-
thiodipentanoylhydroxysuccinimide rearranges to form two potential products: a 6-
membered oxazoline ring and a methyl ether product which forms a characteristic doublet 
with a 47 Da difference. Formation of the oxazoline ring requires an adjacent nitrogen which 
is derived from the amide bond formed during crosslinking with lysine, therefore linkage is 
necessary for fragmentation. 
Important to the development of a general synthetic procedure is the easy incorporation of 
different spacer-arm moieties. The chosen linkers are derived from dicarboxylic acids and 
should therefore be available for coupling to the base unit, 12, followed by NHS esterification. 
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Figure 4: A schematic depicting the fragmentation pathways of three different MS labile 
linkers. 
 
 Linker 3 
Retrosynthetic analysis revealed that a disulphide spacer-arm, linker 3, could be synthesised 
from a peptide coupling with the 12 but previous work highlighted that methyl ester 
hydrolysis with both LiOH and NaOH resulted in decomposition of the disulphide starting 
material,1 a phenomenon that has been noted previously.7,8 To avoid this, an alternative 
synthesis was first trialled whereby di-tert-butylazodicarboxylate (DBAD) protected 3-
mercaptopropionic acid would be coupled with 12. Following ester hydrolysis, introduction 




Figure 5. Retrosynthetic analysis showing synthesis of linker 3 is possible through two ways: 
using a DBAD protecting group and introducing a thioacid or via a coupling with a diacid. 
 
Initial synthesis of the DBAD protected thiol was attempted (Scheme 4) but reaction failed to 
yield any of the desired product. MS analysis did not show the expected ions and NMR 
revealed only a large singlet at 1.45 ppm corresponding to the di-tert butyl group, but showed 
no CH2 triplets indicating the presence of 3-mercaptopropionic acid. 
 
Scheme 4. Synthesis of DBAD protected 3-mercaptopropionic acid. 
 
 
Following the failed attempt at forming the DBAD protected thiol, a peptide coupling with 
3,3’-dithiodipropionic acid was instead attempted, guided by conditions established with 
linker 2 (Scheme 5). This synthesis successfully yielded the final product, linker 3, which was 
immediately used for XL-MS, as described in Chapter 4. 
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Scheme 5. Synthesis of linker 3. 
 
 
 Linker 4/4a 
A new reagent based on the commercially available positive cleavable cross-linker, DSSO was 
considered by retrosynthetic analysis (Fig. 6). The sulfoxide motif could be incorporated 
though the peptide coupling of 3’-thiodipropanoic acid, followed by NHS esterification and 
oxidation of the thioether by meta-chloroperoxybenzoic acid (mCPBA), as described by Kao, 
et al.5 (Scheme 6). 
 
Figure 6. Retrosynthetic analysis of DSSO-based linker. 
 
138 
While formation of the sulphur containing cross-linker chain was a success following the same 
procedure as for linker 3, oxidation with mCPBA was unsuccessful as the compound was 
found to preferentially form the sulfone, rather than the sulfoxide (Scheme 6). This was 
confirmed by HRMS with only the sulfone product, at 552.0887 Da, being detected. To 
determine whether the sulfone would still fragment under CID conditions similarly to the 
sulfoxide, and therefore retain functionality as an MS cleavable linker, the sulfone product 
was crosslinked with a test peptide, AcAAKA and subject to MS/MS analysis. The sulfone 
product was shown not to fragment at the spacer-arm as would be expected with the 
sulfoxide and instead fragment the linked test peptides preferentially. As can be seen in 
Figure 7, the MS/MS spectrum was dominated by b/y ion fragmentation along the peptide 
chain, while the spacer-arm remained intact. Potentially due to the added oxygen enabling 
resonance effects to stabilise the positive charge through CID. 
As only the final oxidation step was unsuccessful, alternative reaction conditions were instead 
trialled to yield a methyl sulfonium product, similar in concept to S-methyl 5,5’-
thiodipentanoylhydroxysuccinimide, but with a three carbon instead of 5 carbon chain. This 
would allow for testing the lability of the spacer-arm as well as extend the synthetic 
procedure. The methyl sulfonium linker was successfully synthesised in one step by methyl 
transfer using methyl iodide (2.2 mol eq.), as per Lu, et al.,6 yielding linker 4a which was used 
for analysis without further purification (Scheme 6). 
 




Following successful synthesis of this linker, 4a, an MS/MS experiment was performed to 
investigate if the linker would fragment as intended. When subject to CID, the compound 
rearranged to form a 4-membered oxazoline ring, confirming the reaction as well as 
compatibility between the serine base unit and a methyl sulfonium containing spacer-arm. 
On top of this, the data showcases the first time a shorter carbon chain has been used as a 
methyl sulfonium based cleavable crosslinker. 
 
Figure 7. (A) Increasing CID energy instead lead to preferential fragmentation of the peptide 
backbone, rather than the spacer-arm. (B) When the sulphur was methylated, rather than 
oxidised, the spacer-arm fragmented preferentially upon increased CID energy, rearranging 
to form a 4-membered oxazoline ring. 
 
Showing the linker design for a labile spacer-arm based on the fixed-charge methyl sulfonium 
ion was feasible, a longer version of the linker using 5,5’-thiodipentanoic acid, as per the 
design by Lu, et al.,6 was synthesised. This design initially included peptide coupling with a 
mono-methyl ester derivative of 5,5’-thiodipentanoic acid, 5-((5-methoxy-5-
oxopentyl)thio)pentanoic acid, as this would help reduce diaddition products arising if the 
serine unit could attack either side of the acid. The thioether synthesis was trialled (Fig. 8) 
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using Et3N in DCM as well as K2CO3 and 12 crown-4-ether. Neither combination yielded the 
desired monoester/-acid product and therefore the diacid, 5,5’-thiodipentanoic acid, was 
coupled to the amine, 12, by activation with HATU instead. This successfully yielded the 
desired amide which, following deprotection and methylation with methyl iodide, yielded 
Linker 4, which was used for crosslinking reactions, as described in Chapter 4, without further 
purification (Scheme 7). 
 
Figure 8. Retrosynthetic analysis of linker 4. 
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5.5 Conclusions and future directions 
Combining the knowledge gathered through the successful synthesis of five cross-linking 
reagents, a general synthetic procedure was generated (Scheme 8). It was important to keep 
this synthetic procedure as consistent as possible, through the coupling of diacids (and 
monoacid/-esters), rather than unique syntheses for each spacer arm to ensure the protocol 
is simple to follow and therefore widely accessible. Based on the previous reactions, the 
general synthetic procedure developed is capable of handling the synthesis of all considered 
spacer-arm combinations, with an additional methylation step for linker 4 and 4a. The 
flexibility of the peptide coupling allows for the incorporation of any acid based spacer-arm 
but could also allow for incorporation of a diazirine for non-specific heterobifunctional cross-
linking. The esterification reaction allows for diversity wherein any ester-based reactive group 
can be incorporated. Finally, the alkyne tag allows for the ability to directly bind DBCO 
Sepharose beads directly for enrichment,10 but could also be derivatised by biotin azide or 
azido-PEG3-phosphonic acid for avidin or IMAC affinity chromatography, respectively. 
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The work demonstrated in this chapter reflects on the considerations which developed the 
groundwork toward the synthesis of a more comprehensive range of cross-linker reagents, as 
shown in Chapter 4, that can be applied to biological samples. The advantages of diverse 
cross-linker choices may help to address some current analytical challenges with regards to 
XL-MS. 
 





5.6 Materials and methods 
 Materials and reagents 
Chemicals were purchased from Merck (Kenilworth,  U.S.A.) or AK Scientific (Union City, 
U.S.A.). The peptide AcAAKA was synthesised in-house using standard Fmoc solid-phase 
methods on 2-chlorotrityl chloride resin (GL Biochem, Shanghai, China) and purified by high-
performance liquid chromatography (HPLC) to greater than 95% purity as described 
previously.4 
 Cross-linking of AcAAKA 
Each linker was dissolved in DMSO to 10 mM with AcAAKA in a 1:1 linker:peptide ratio with 1 
eq. of diisopropylethylamine. The mixture was incubated at room temperature for 1 h. The 
mixture was then diluted to 10 µM in 1:1 water:acetonitrile for analysis by negative ion mode 
tandem MS and with 0.1 % aqueous formic acid for analysis by positive ion mode tandem MS.  
 Tandem mass spectrometry 
MS/MS spectra were collected using a Micromass Q-ToF 2 mass spectrometer (Waters, 
Manchester, UK)  using a nano-electrospray ionisation source. Samples were prepared in 1:1 
water:acetonitrile at a concentration of 10 µM. Samples were loaded into platinum-coated 
borosilicate glass capillaries prepared in-house. Instrument parameters as follows: capillary 
voltage, 1.60 kV; sampling cone, 30 V; extraction cone, 1.5 V; trap/transfer collision energy, 
10/15 V; trap gas, 5.5 l/h; backing gas, ∼4.5 mbar, collision energy 10 V. For CID, collision 
energy was increased to 50 V. Mass spectra were viewed using MassLynx (v4.1) (Waters 
Corporation, Manchester, U.K.). 
 High-resolution mass spectrometry 
High-resolution mass spectra were collected using an Agilent Technologies 6230 Accurate-
Mass TOF spectrometer and were visualised using Qualitative Analysis (Version B.06.00) 




5.7 Synthetic methods 
 Compound 12 
(S)-2-((tert-butoxycarbonyl)amino)-3-(prop-2-yn-1-yloxy)propanoic acid (11) 
 
Compound 12 was synthesised by dissolving Boc-L-Serine) in DMF (50 mL per 1 g) and stirring 
on ice for 15 min. A 60 % wt/wt dispersion of sodium hydride (2.5 mol eq.) was added and the 
solution was stirred on ice for 45 min. The reaction mixture was allowed to warm to room 
temperature and then stir overnight under a nitrogen atmosphere. Water (15 mL) was added 
and stirred for 5 minutes. The solution was washed with diethyl ether, acidified to <3 pH with 
1 M KHSO4 and then extracted with ethyl acetate (3x 30 mL). The combined extracts were 
washed with water and dried over Na2SO4. The solvent was removed in vacuo to yield 11 as a 
yellow oil which was used without further purification with a yield of 91 %. 
1H NMR (500 MHz, DMSO-d6, δ): 8.64 (br s, 3H), 4.37 (t, J = 3.3 Hz, 1H), 4,24 (dd, J = 16.1, 2.2 
Hz ,1H), 4.20 (dd, J = 16.1, 2.2 Hz, 1H), 3.91 (dd, J = 10.5, 4.1 Hz, 1H), 3.85 (dd, J = 10.5, 3.0 Hz, 
1H), 3.76 (s, 3H), 3.56 (t, J = 2.1 Hz, 1H) 
All NMR data is consistent with literature.11 
 
(S)-methyl 2-amino-3-(prop-2-yn-1-yloxy)propanoate (12) 
 
The acid (11) was dissolved in methanol (50 mL per 1 g) and stirred on ice for 15 min. Thionyl 
chloride was then added dropwise (2 mol eq.) under a nitrogen atmosphere. The solvent was 
removed in vacuo and the residue was co-evaporated with methanol three times to yield 
compound 12 as an orange oil, with a yield of 97 %. 
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1H NMR (500 MHz, DMSO-d6, δ): 8.64 (br s, 3H), 4.37 (t, J = 3.3 Hz, 1H), 4.24 (dd, J = 16.1, 2.2 
Hz, 1H), 4.20 (dd, J = 16.1, 2.2 Hz, 1H), 3.91 (dd, J = 10.5, 4.1 Hz, 1H), 3.85 (dd, J = 10.6, 3.0 Hz, 
1H), 3.76 (s, 3H) 3.56 (t, J = 2.1 Hz, 1H). 13C NMR (125 MHz, CD3OD, δ): 168.7, 79.4, 77.2, 67.6, 
59.4, 54.3, 53.9. All NMR data is consistent with literature.12 
 
 Succinimide linker 
(S)-methyl 4-((1-methoxy-1-oxo-3-(prop-2-yn-1-yloxy)propan-2-yl)amino)-4-oxobutanoate 
 
12 was dissolved in tetrahydrofuran (THF) (5 mL per 100 mg) with diisopropylethylamine 
(DIPEA) (4.0 mol eq) while stirring. Succinic anhydride (1.0 mol eq.) was added to the solution 
followed by HATU (1.2 mol eq.). The mixture was stirred overnight at room temperature 
under a nitrogen atmosphere. 1 M HCl (5 mL per 100 mg) was added and then extracted with 
ethyl acetate (1.5 mL per 100 mg, 3×). The organic phase was washed with water (3×) and 
brine then dried over N2SO4 and the solvent was removed in vacuo. As this would yield a 
monoacid/-ester the crude product was esterifying to aid in purification. The crude product 
was dissolved in methanol (50 mL per 1 g) and stirred on ice for 15 min. Thionyl chloride was 
then added dropwise (2.0 mol eq.) under a nitrogen atmosphere. The solvent was removed 
in vacuo and the residue was co-evaporated with methanol three times. The crude product 
was then purified by flash chromatography on normal phase silica to yield the desired amide 
17 with a yield of 38%. 
1H NMR (500 MHz, CDCl3, δ): 4.75 (dt, J = 8.2, 3.2 Hz, 1H), 4.12 (d, J = 2.4 Hz, 2H), 3.94 (dd, J = 
9.5, 3.2 Hz, 1H), 3.74 (s, 3H), 3.78 – 3.71 (m, 1H), 3.67 (s, 3H), 2.68 – 2.53 (m, 4H), 2.45 (t, J = 







The amide 16 was dissolved in THF (1 mL per 100 g) and stirred on ice for 15 minutes. 1 M 
LiOH (4 mol eq.) was added and the reaction was stirred until completion determined by thin 
layer chromatography (TLC). The solvent was removed in vacuo and the residue was 
partitioned between DCM and water. The organic layer was isolated and the aqueous layer 
was extracted with DCM (2×). The combined organic extracts were washed with brine and 
dried over N2SO4. The solvent was removed in vacuo to yield the desired diacid (17) as a yellow 
oil with a yield of 80%. 
1H NMR (500 MHz, CDO3D, δ):  δ 4.63 (t, J = 4.2 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.93 (dd, J = 




TFA-NHS was synthesised by dissolving NHS in toluene (20 mL per gram). TFA was added (1.2 
eq.) and the mixture was refluxed for 5 h. The solvent was removed in vacuo to yield TFA-NHS 
as a white crystalline solid in near quantitative yield. 
1H NMR (500 MHz, CDCl3, δ) 2.92 (s, 4H). 





 Linker 1 
(S)-methyl 6-((1-methoxy-1-oxo-3-(prop-2-yn-1-yloxy)propan-2-yl)amino)-6-oxohexanoate 
 
12 was dissolved in tetrahydrofuran (THF) (5 mL per 100 mg) with diisopropylethylamine 
(DIPEA) (4.0 mol eq) while stirring. Monomethyl adipate (1.0 mol eq.) was added to the 
solution followed by HATU (1.2 mol eq.). The mixture was stirred overnight at room 
temperature under a nitrogen atmosphere. 1 M HCl (5 mL per 100 mg) was added and then 
extracted with ethyl acetate (1.5 mL per 100 mg, 3×). The organic phase was washed with 
water (3×) and brine then dried over N2SO4 and the solvent was removed in vacuo. 
The crude product was then purified by flash chromatography on normal phase silica to yield 
the desired amide with a yield of 19%. 
1H NMR (500 MHz, CDCl3, δ): 6.29 (d, J = 7.9 Hz, 1H), 4.79 (dt, J = 8.1, 3.1 Hz, 1H), 4.15 (dd, 
2H), 3.97 (dd, J = 9.4, 3.1 Hz, 1H), 3.82 – 3.74 (m, 4H), 3.67 (s, 3H), 2.46 (t, J = 2.4 Hz, 1H), 2.34 
(t, J = 6.9 Hz, 2H), 2.28 (t, J = 6.4 Hz, 2H), 1.75 – 1.61 (m, 4H). 
13C NMR (125 MHz, CDCl3, δ): 174.0, 172.5, 170.7, 79.0, 75.3, 69.6, 58.7, 52.8, 52.4, 51.7, 36.1, 




The amide was dissolved in THF (1 mL per 100 g) and stirred on ice for 15 minutes. 1 M LiOH 
(4 mol eq.) was added and the reaction was stirred until completion determined by thin layer 
chromatography (TLC). The solvent was removed in vacuo and the residue was partitioned 
between DCM and water. The organic layer was isolated and the aqueous layer was extracted 
with DCM (2×). The combined organic extracts were washed with brine and dried over N2SO4. 
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The solvent was removed in vacuo to yield the desired diacid as a yellow oil with a yield of 
79%. 
1H NMR (500 MHz, CD3OD, δ): 4.63 (t, J = 4.2 Hz, 1H), 4.18 (d, J = 2.4 Hz, 2H), 3.91 (dd, J = 9.6, 
5.0 Hz, 1H), 3.79 (dd, J = 9.6, 3.6 Hz, 1H), 2.86 (t, J = 2.4 Hz, 1H), 2.31 (q, J = 7.0 Hz, 4H), 1.71 
– 1.59 (m, 4H). 





The diacid was dissolved in anhydrous THF (10 mL per 100 mg) with EDC-HCl (3.4 mol eq) and 
stirred at room temperature for 10 minutes. NHS was (6 eq.) added and the reaction was 
stirred at room temperature under a nitrogen atmosphere overnight. The solvent was 
removed in vacuo and the resulting residue was partitioned between DCM and water. The 
aqueous layer was extracted with DCM (3x) and the combined organic extracts were dried 
over MgSO4 and filtered. The solvent was removed from the filtrate in vacuo to afford the 
ester, which was used for cross-linking reactions without further purification. 








 Linker 2 
(S)-7-((1-methoxy-1-oxo-3-(prop-2-yn-1-yloxy)propan-2-yl)amino)-7-oxoheptanoic acid 
 
12 was dissolved in tetrahydrofuran (THF) (5 mL per 100 mg) with diisopropylethylamine 
(DIPEA) (4.0 mol eq) while stirring. Heptanedioic acid (1.0 mol eq.) was added to the solution 
followed by HATU (1.2 mol eq.). The mixture was stirred overnight at room temperature 
under a nitrogen atmosphere. 1 M HCl (5 mL per 100 mg) was added and then extracted with 
ethyl acetate (1.5 mL per 100 mg, 3×). The organic phase was washed with water (3×) and 
brine then dried over N2SO4 and the solvent was removed in vacuo. 
The crude product was then purified by flash chromatography on normal phase silica to yield 
the desired amide with a yield of 16%. 
1H NMR (500 MHz, CD3OD, δ): 4.71 (dt, J = 5.1, 3.7 Hz, 1H), 4.22 (dd, J = 2.4, 0.8 Hz, 2H), 3.95 
(dd, J = 9.7, 5.1 Hz, 1H), 3.81 (dd, J = 9.7, 3.8 Hz, 1H), 3.78 (s, 3H), 2.92 (t, J = 2.4 Hz, 1H), 2.33 
(q, J = 7.4 Hz, 4H), 1.74 – 1.62 (m, 4H), 1.48 – 1.35 (m, 2H) 
13C NMR (125 MHz, CD3OD, δ): 178.7, 177.5, 173.1, 81.3, 77.6, 71.3, 60.4, 55.2, 54.1, 37.6, 




The amide was dissolved in THF (1 mL per 100 g) and stirred on ice for 15 minutes. 1 M LiOH 
(4 mol eq.) was added and the reaction was stirred until completion determined by thin layer 
chromatography (TLC). The solvent was removed in vacuo and the residue was partitioned 
between DCM and water. The organic layer was isolated and the aqueous layer was extracted 
with DCM (2×). The combined organic extracts were washed with brine and dried over N2SO4. 
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The solvent was removed in vacuo to yield the desired diacid as a yellow oil with a yield of 
79%. 
 
1H NMR (500 MHz, CD3OD, δ): 4.64 (dt, J = 5.0, 3.6 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.92 (dd, J 
= 9.6, 5.0 Hz, 1H), 3.80 (dd, J = 9.6, 3.7 Hz, 1H), 2.87 (t, J = 2.4 Hz, 1H), 2.30 (td, J = 7.5, 3.7 Hz, 
4H), 1.92 – 1.83 (m, 4H), 1.64 (dp, J = 11.8, 7.5 Hz, 2H) 
13C NMR (125 MHz, CD3OD, δ): 178.8, 177.4, 174.3, 81.4, 77.6, 71.5, 60.5, 55.1, 37.7, 36.0, 




The diacid was dissolved in anhydrous THF (10 mL per 100 mg) with EDC-HCl (3.4 mol eq) and 
stirred at room temperature for 10 minutes. NHS was (6 eq.) added and the reaction was 
stirred at room temperature under a nitrogen atmosphere overnight. The solvent was 
removed in vacuo and the resulting residue was partitioned between DCM and water. The 
aqueous layer was extracted with DCM (3x) and the combined organic extracts were dried 
over MgSO4 and filtered. The solvent was removed from the filtrate in vacuo to afford the 
NHS ester, Linker 2, which was used for cross-linking reactions without further purification. 










12 was dissolved in tetrahydrofuran (THF) (5 mL per 100 mg) with diisopropylethylamine 
(DIPEA) (4.0 mol eq) while stirring. 3,3'-dithiodipropanoic acid (1.0 mol eq.) was added to the 
solution followed by HATU (1.2 mol eq.). The mixture was stirred overnight at room 
temperature under a nitrogen atmosphere. 1 M HCl (5 mL per 100 mg) was added and then 
extracted with ethyl acetate (1.5 mL per 100 mg, 3×). The organic phase was washed with 
water (3×) and brine then dried over N2SO4 and the solvent was removed in vacuo. 
The crude product was then purified by flash chromatography on normal phase silica to yield 
the desired amide with a yield of 16%. 
1H NMR (500 MHz, CD3OD, δ): 4.71 (dt, J = 5.1, 3.7 Hz, 1H), 4.22 (dd, J = 2.4, 0.8 Hz, 2H), 3.95 
(dd, J = 9.7, 5.1 Hz, 1H), 3.81 (dd, J = 9.7, 3.8 Hz, 1H), 3.78 (s, 3H), 2.92 (t, J = 2.4 Hz, 1H), 2.33 
(q, J = 7.4 Hz, 4H), 1.74 – 1.62 (m, 4H), 1.48 – 1.35 (m, 2H) 
13C NMR (125 MHz, CD3OD, δ): 178.7, 177.5, 173.1, 81.3, 77.6, 71.3, 60.4, 55.2, 54.1, 37.6, 




The amide was dissolved in THF (1 mL per 100 g) and stirred on ice for 15 minutes. 1 M LiOH 
(4 mol eq.) was added and the reaction was stirred until completion determined by thin layer 
chromatography (TLC). The solvent was removed in vacuo and the residue was partitioned 
between DCM and water. The organic layer was isolated and the aqueous layer was extracted 
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with DCM (2×). The combined organic extracts were washed with brine and dried over N2SO4. 
The solvent was removed in vacuo to yield the desired diacid as a yellow oil with a yield of 
83%. 
1H NMR (500 MHz, CD3OD, δ): 4.66 (t, J = 4.2, 4.2 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.94 (dd, J = 
9.7, 4.8 Hz, 1H), 3.80 (dt, J = 9.8, 2.8 Hz, 1H), 3.01 – 2.90 (m, 4H), 2.72 (tt, J = 7.0, 3.2 Hz, 4H). 






The diacid was dissolved in anhydrous THF (10 mL per 100 mg) with EDC-HCl (3.4 mol eq) and 
stirred at room temperature for 10 minutes. NHS was (6 eq.) added and the reaction was 
stirred at room temperature under a nitrogen atmosphere overnight. The solvent was 
removed in vacuo and the resulting residue was partitioned between DCM and water. The 
aqueous layer was extracted with DCM (3x) and the combined organic extracts were dried 
over MgSO4 and filtered. The solvent was removed from the filtrate in vacuo to afford the 
ester, 3, which was used for cross-linking reactions without further purification. 










12 was dissolved in tetrahydrofuran (THF) (5 mL per 100 mg) with diisopropylethylamine 
(DIPEA) (4.0 mol eq) while stirring. 3,3'-thiodipropanoic acid (1.0 mol eq.) was added to the 
solution followed by HATU (1.2 mol eq.). The mixture was stirred overnight at room 
temperature under a nitrogen atmosphere. 1 M HCl (5 mL per 100 mg) was added and then 
extracted with ethyl acetate (1.5 mL per 100 mg, 3×). The organic phase was washed with 
water (3×) and brine then dried over N2SO4 and the solvent was removed in vacuo. 
The crude product was then purified by flash chromatography on normal phase silica to yield 
the desired amide with a yield of 37%. 
1H NMR (500 MHz, CD3OD, δ): 4.69 (dt, J =  3.81, 1.1 Hz, 1H), 4.18 (t, J = 2.3 Hz, 1H), 3.93 (dd, J 
= 9.6, 4.7 Hz, 1H), 3.77 (dd, J = 9.7, 3.7 Hz, 1H), 3.75 (s, 3H), 2.89 (t, J = 2.4 Hz, 1H), 2.80 (td, J 
= 7.3, 2.9 Hz, 4H), 2.64 (t, J = 7.1 Hz, 2H), 2.58 (t, J = 7.2 Hz, 2H).  
13C NMR (125 MHz, CDCl3, δ): 179.10, 173.91, 173.25, 81.41, 77.91, 72.05, 61.28, 55.46, 55.14, 




The amide was dissolved in THF (1 mL per 100 g) and stirred on ice for 15 minutes. 1 M LiOH 
(4 mol eq.) was added and the reaction was stirred until completion determined by thin layer 
chromatography (TLC). The solvent was removed in vacuo and the residue was partitioned 
between DCM and water. The organic layer was isolated and the aqueous layer was extracted 
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with DCM (2×). The combined organic extracts were washed with brine and dried over N2SO4. 
The solvent was removed in vacuo to yield the desired diacid as a yellow oil with near 
quantitative yield. 
1H NMR (500 MHz, CD3OD, δ): 4.66 (dt, J = 3.6, 1.1 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.94 (dd, J 
= 9.6, 4.7 Hz, 1H), 3.79 (dd, J = 9.6, 3.6 Hz, 1H), 2.81 (dt, J = 10.1, 7.2 Hz, 4H), 2.60 (td, J = 7.2, 
5.3 Hz, 4H). 






The diacid was dissolved in anhydrous THF (10 mL per 100 mg) with EDC-HCl (3.4 mol eq) and 
stirred at room temperature for 10 minutes. NHS was (6 eq.) added and the reaction was 
stirred at room temperature under a nitrogen atmosphere overnight. The solvent was 
removed in vacuo and the resulting residue was partitioned between DCM and water. The 
aqueous layer was extracted with DCM (3x) and the combined organic extracts were dried 
over MgSO4 and filtered. The solvent was removed from the filtrate in vacuo to afford the 
NHS ester. The NHS ester was dissolved in chloroform (5 mL per 100 mg) at 0 °C and mixed 
with a solution of m-chloroperbenzoic acid (1 mol eq.) (3 mL per 100 mg). The solution was 
stirred for 5 minutes then solvent was removed in vacuo and the product was purified by flash 
chromatography on normal phase silica to yield the desired NHS that was used for cross-
linking reactions immediately. 
HRMS (ESI+) calculated for C20H23N4O12S [M+Na]+ = 552.0900, found [M+Na]+: 552.0887 
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 Linker 4 
5-mercaptopentanoic acid 
 
Based on synthetic procedures described by Lu, et al. (2008),6 5-bromovaleric acid and 
thiourea (1.5 mol eq.) were dissolved in ethanol (10 mL per 1 g) and refluxed for 20 h. The 
solvent was removed under reduced pressure and 7.5 M NaOH (aq) (15 mol eq.) was added. 
The mixture was stirred for 16 h at 90 °C. The mixture was cooled on ice and 2 M H2SO4 was 
added dropwise while stirring until pH 1. The product was then extracted with 
dichloromethane (2 × 100 mL). The combined organic extracts were dried over MgSO4 and 
filtered. The solvent was removed from the filtrate in vacuo to afford 5-mercaptopentanoic 
acid as a colourless oil in near quantitative yield. The product was used without further 
purification. 
1H NMR (500 MHz, CDCl3, δ): 11.29 (s br, 1H), 2.59 – 2.51 (m, 2H), 2.38 (t, J = 7.1 Hz, 2H), 1.80 
– 1.62 (m, 4H), 1.36 (td, J = 7.9, 1.1 Hz, 1H). 




Using synthesis described in Lu, et al. (2008),6 a solution of 5-bromovaleric acid in 16.7 M 
NaOH (2 mL per 1 g) was added dropwise to a mixture of 5-mercaptopentanoic acid in 16.7 
M (2 mL per 1g). The mixture was stirred at 45 °C for 24 h. The mixture was cooled to room 
temperature and acidified to pH 1 with concentrated hydrochloric acid. The product was 
extracted with dichloromethane (5 × 50 mL) and the combined organic extracts were dried 
over MgSO4 and filtered. The solvent was removed from the filtrate in vacuo to afford 5, 5’-
thiodipentanoic acid as a white solid with a yield of 86%. 
1H NMR (500 MHz, CDCl3, δ): 2.54 (t, J = 7.2 Hz, 4H), 2.40 (t, J = 7.2 Hz, 4H), 1.80 – 1.61 (m, 
8H). 
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13C NMR (125 MHz, CDCl3, δ): 177.46, 36.02, 30.88, 27.00, 22.09. 





12 was dissolved in tetrahydrofuran (THF) (5 mL per 100 mg) with diisopropylethylamine 
(DIPEA) (4.0 mol eq) while stirring. 5, 5'-thiodipentanoic acid (1.0 mol eq.) was added to the 
solution followed by HATU (1.2 mol eq.). The mixture was stirred overnight at room 
temperature under a nitrogen atmosphere. 1 M HCl (5 mL per 100 mg) was added and then 
extracted with ethyl acetate (1.5 mL per 100 mg, 3×). The organic phase was washed with 
water (3×) and brine then dried over N2SO4 and the solvent was removed in vacuo. 
The crude product was then purified by flash chromatography on normal phase silica to yield 
the desired amide with a yield of 20%. 
1H NMR (500 MHz, CD3OD, δ): 4.67 (dt, J = 3.60, 1.37 Hz, 1H), 4.18 (d, J = 2.4 Hz, 2H), 3.92 (dd, 
J = 9.7, 5.0 Hz, 1H), 3.77 (dd, J = 9.7, 3.8 Hz, 1H), 3.74 (s, 3H), 2.89 (t, J = 2.4 Hz, 1H), 2.59 – 
2.51 (m, 4H), 2.31 (q, J = 7.3 Hz, 4H), 1.78 – 1.57 (m, 8H). 
13C NMR (125 MHz, CD3OD, δ): 178.3, 176.3, 175.9, 83.1, 81.5, 72.6, 61.7, 55.9, 55.9, 38.2, 




The amide was dissolved in THF (1 mL per 100 g) and stirred on ice for 15 minutes. 1 M LiOH 
(4 mol eq.) was added and the reaction was stirred until completion determined by thin layer 
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chromatography (TLC). The solvent was removed in vacuo and the residue was partitioned 
between DCM and water. The organic layer was isolated and the aqueous layer was extracted 
with DCM (2×). The combined organic extracts were washed with brine and dried over N2SO4. 
The solvent was removed in vacuo to yield the desired diacid as a yellow oil with 67% yield. 
1H NMR (500 MHz, CD3OD, δ): 4.63 (t, J = 4.3 Hz, 1H), 4.19 (d, J = 2.4 Hz, 2H), 3.91 (dd, J = 9.6, 
5.0 Hz, 1H), 3.80 (dd, J = 9.6, 3.6 Hz, 1H), 2.87 (t, J = 2.5 Hz, 1H), 2.54 (t, J = 7.1 Hz, 4H), 2.31 
(q, J = 6.8 Hz, 4H), 1.78 – 1.66 (m, 4H), 1.63 (ddt, J = 12.1, 7.7, 5.0 Hz, 4H). 
13C NMR (125 MHz, CD3OD, δ): 178.3, 176.1, 175.4, 83.8, 81.5, 73.0, 61.7, 55.9, 38.3, 37.1, 
34.6, 34.6, 32.5, 32.5, 28.4, 27.6. 
(5-(((S)-1-((2,5-dioxopyrrolidin-1-yl)oxy)-1-oxo-3-(prop-2-yn-1-yloxy)propan-2-yl)amino)-5-
oxopentyl)(5-((2,5-dioxopyrrolidin-1-yl)oxy)-5-oxopentyl)(methyl)sulfonium iodide (4) 
 
The diacid was dissolved in anhydrous THF (10 mL per 100 mg) with EDC-HCl (3.4 mol eq) and 
stirred at room temperature for 10 minutes. NHS was (6 eq.) added and the reaction was 
stirred at room temperature under a nitrogen atmosphere overnight. The solvent was 
removed in vacuo and the resulting residue was partitioned between DCM and water. The 
aqueous layer was extracted with DCM (3x) and the combined organic extracts were dried 
over MgSO4 and filtered. The solvent was removed from the filtrate in vacuo to afford the 
NHS ester. The NHS ester was dissolved in acetonitrile (ACN) (1 mL per 100 mg) followed by 
methyl iodide (2.2 mol eq.) and left stirring under a N2 atmosphere for 4 days successfully 
yielding linker 4a, which was used for crosslinking reactions without further purification. 
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Chapter 6: Summary, Conclusion and Future Directions 
The focus of this thesis was to utilise an MS-based approached to better understand 
structures and interactions of proteins that are notoriously complicated to analyse with 
traditional structure determination techniques. Overall, the work here highlights the power 
of utilising an MS-based approach to tackle unique protein structure challenges, in particular 
for misfolding proteins whose intrinsic disorder demands an analytical technique capable of 
great adaptability. 
 
6.1 β-CN stabilises both amorphous and fibrillar α-LA 
The ability to monitor both amorphous and fibrillar aggregation from a single protein allows 
greater insight into the structural behaviour that designates which pathway it will take. This 
is of much interest as amorphous aggregates are widely regarded and non-toxic, while fibrillar 
aggregates are associated with a wide range of neurodegenerative diseases. Understanding 
the contrasting changes in structural effects that dictate a mode of aggregation may have 
implications in disease understanding or identification of therapeutic targets for drug design. 
The molecular chaperone β-CN was shown to inhibit the aggregation of both fibrillar RCM α-
LA and amorphous DTT α-LA, with a greater efficacy observed toward RCM α-LA. Intrinsic and 
extrinsic fluorescence studies reveal differences in the two forms of α-LA, where DTT α-LA 
exposed far greater levels of hydrophobicity but exhibited native-like levels of tryptophan 
residues suggesting a molten-globule like state that undergoes rapid amorphous aggregation 
due to random interactions from exposed hydrophobicity. On the other hand, RCM α-LA 
indicated a lack of native structure, through a change in tryptophan fluorescence, but exposed 
little hydrophobic content. The unravelling in structure but lack of exposed hydrophobicity 
may be important to the fibrillation mechanism as RCM α-LA fibril formation is a slower 
process with a relatively lengthy nucleation phase, compared with amorphous aggregation. 
This may be important to fibrillar aggregation of RCM α-LA by striking a balance between 
avoiding the faster process of amorphous aggregation, due to fewer contacts between 
hydrophobic residues, while also remaining destabilised enough to sample off-pathway 
conformations during the lag phase before nucleation. 
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Although β-CN inhibited both forms of α-LA aggregation, it was more effective towards 
fibrillar RCM α-LA. Unlike DTT α-LA,1–3 RCM α-LA was not shown to form a HMW complex by 
analysis SEC. IM-MS instead revealed that RCM α-LA was transiently stabilised by β-CN. CIU 
analysis revealed that RCM α-LA required lower CID voltages to induce unfolding than native 
α-LA but when RCM α-LA was subject to CIU in the presence of β-CN the unfolding voltage 
increased, suggesting β-CN afforded greater structural stability to RCM α-LA, despite no non-
covalent interactions being observed by native MS. Overall, this data infers β-CN operates 
through two distinct mechanisms, depending on the mode of aggregation. β-CN locks DTT α-
LA, in the form of a disordered molten globule, into a HMW complex while the partially 
unfolded intermediate of RCM α-LA is afforded structural stability through transient 
interactions with β-CN. Furthermore, this work highlights the power of CIU as a technique for 
investigating the effects on protein stability from molecular chaperones. 
The application of CIU toward chaperone-protein interactions is underrepresented and could 
give a better understand to a whole host of protein-protein interactions. This technique is 
particularly suited for the examination of chaperones and inhibition relationships of 
misfolded proteins that still retain structure and therefore unfolding can be visualised, yet are 
still too dynamic for other techniques. 
6.2 Lipids reduce fibril inhibitor efficacy of Aβ40 and αS 
Current understanding implicates oligomeric, misfolding proteins interacting with lipid 
membranes in aetiology of misfolding diseases. Many studies have been conducted on Aβ40 
and αS, the proteins associated with Alzheimer’s and Parkinson’s disease respectively, to 
better understand potentially deleterious effects from lipid membrane interactions.4–7 
Natural polyphenols are of interest in drug development due to their notable anti-amyloid 
effects8,9 with EGCG9–12 and resveratrol13,14 being two prototypical examples. In this work, 
LUVs, one zwitterionic (PC) and one anionic (PCPG), were used as models for a lipid 
environment. Using ThT fluorescence assays, both LUV types were shown to increase fibrillar 
aggregation, with anionic lipids having a greater effect. LUVs were also shown to decrease the 
efficacy of both EGCG and resveratrol, with anionic LUVs again having a greater impact.  
Oligomer specific immunoblotting revealed that EGCG reduced oligomeric content of Aβ40 
and αS more effectively that resveratrol. This may be explained by EGCG having been 
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previously shown to affect oligomeric misfolding species,9–12 while resveratrol has been 
described as inhibiting through a capping mechanism, preventing the elongation rather than 
nucleation of misfolding proteins.15–17 
Finally, native MS and IM-MS was used to characterise non-covalent interactions and 
structural changes. Native MS showed that EGCG formed complexes with Aβ40 and αS, while 
resveratrol did not. IM-MS showed EGCG induced structural compaction across multiple 
charge states of Aβ40 and αS, a phenomenon witnessed before the initiation of fibrillar 
aggregation.18–20 In contrast, EGCG interacted with compact forms of monomeric Aβ40 and 
αS, decreasing structural homogeneity. The direct competition between the structural effects 
of EGCG and LUVs may explain why inhibitory efficacy was reduced. Furthermore, as 
resveratrol inhibits more directly within the elongation phase, it cannot counter the effects 
of a lipid environment as effectively as EGCG. This could potentially explain its poorer 
performance as an inhibitor. 
Overall, this work added insight into the poorly understood relationship between lipid 
membranes and misfolding proteins as well as highlighting the importance of considering 
lipids in aggregation inhibition studies. This study emphasizes that if the lipid environment is 
not taken into account during therapeutic design, the outcome may result in an ineffective 
treatment. 
Further work is required to better understand the relationship between lipids, misfolding 
proteins and inhibitors. Utilising more protein models and inhibitors not based on natural 
polyphenols could yield more insight into these mechanisms. On top of this, different or more 
realistic lipid models, such as lipid nanodiscs and total brain lipid extract derived LUVs could 
reveal more about what different lipid characteristics can do to fibrillar inhibition. 
6.3 Development of a modular protocol and linker library to expand XL-MS 
opportunities 
XL-MS is fast emerging as one of the most important MS-based techniques, capable of 
handling proteins that are highly dynamic, like misfolding proteins.21–23 In particular, the 
power of this technique lies in its ability to be combined with higher-resolution techniques, 
like cryo-EM.24 To tackle gaps in the reagent toolset of XL-MS a modular synthetic protocol 
was designed to greatly expand the range of available cross-linker options that are currently 
163 
available. Centred around an amino acid base unit, derived from alkyne-modified serine or 
azide-modified lysine residues, spacer-arms can be peptide coupled followed by esterification 
with a reactive group. Furthermore, the azide/alkyne motifs allow for the possibility of post-
linkage functionalisation opportunities. Using acid-based spacer-arms and hydroxyl-based 
reactive groups, a library of 8 linkers was synthesised. These linkers were tested on model 
peptides and proteins to showcase their linkage, labile spacer-arm fragmentation and post-
linkage derivatisation with enrichment and dye tags. In summary, the described synthetic 
protocol aimed to increase the diversity of cross-linking reagents to better supplement the 
incredibly varied requirements of XL-MS experiments.  
Development of the modular protocol for synthesis of XL-MS reagents leaves by design almost 
limitless opportunities for production of further derivatives, and hence the extended scope 
was too large to be explored entirely and much remains to be done. Potential routes to be 
explored include the expansion of reactive groups, particular those developed by Gutierrez, 
et al.25,26 which require only a single reaction with the NHS esters already synthesised in 
Chapters 4 and 5. Following this, Linker 4a showed, for the first time, the ability to form a 
labile 4-membered oxazoline fragmentation product. This would allow for a shorter chain 
length, fragmentable linker that is intrinsically charged, which may increase ionisability. 
Further optimisation of this linker could uncover its benefits as a useful reagent. Finally, due 
to linker base unit consisting of amino acids using isotopically labelled amino acids would 
allow for quantitation and characteristic identification.27,28 
To conclude, many proteins are not amenable to traditional structure determination 
techniques but the need to understand their structure to aid in disease research and 
therapeutic development remains. MS is a powerful compliment, or alternative, to those 
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